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Abstract
Polymeric vehicles for the optimal delivery of synergistic chemotherapeutics
by
Douglas R. Vogus
Combination chemotherapy is the current gold standard for treating advanced malignan-
cies, but treatment is often limited by systemic toxicity. Polymeric delivery vehicles have
emerged as a useful tool to deliver chemotherapeutics with greater tumor selectivity and re-
duced healthy tissue toxicity than standard chemotherapy. As a result, many nano-sized poly-
meric systems containing a single drug have recently entered clinical trials for the treatment
of advanced cancers; however, few have been approved due to lack of improvements in tumor
regression. This thesis focuses on engineering more therapeutically active polymeric vehicles
by optimally delivering combinations of synergistic chemotherapy drugs. Polymer drug con-
jugates and bi-phasic nanoparticles are engineered to precisely deliver synergistic drugs, and
I show that relative drug release rates govern the therapeutic activity of a given combination
delivery vehicle. I further show that combination polymer drug conjugates can effectively in-
hibit the growth of an aggressive, orthothopic tumor model in vivo more effectively than single
drug conjugates and the free drug combination. The conjugates are capable of preventing tu-
mor growth through various parenteral administration routes, motivating future development
for clinical translation.
In addition to new vehicle development, continued improvements in therapeutic activity
rely on fundamentally understanding the mechanisms by which vehicles interact with biologi-
cal systems and release their therapeutic payloads. In the latter part of this thesis, I develop a
microfluidic technique capable of measuring concentration profiles with high spatio-temporal
resolution. The technique is used to measure the transport of a model drug in hydrogels. I show
viii
that interactions between the polymeric mesh and the solute significantly impact solute trans-
port and resulting drug release properties. Understanding the physical mechanisms in which
drugs interact with their carrier can govern drug release kinetics and is critical for the future
development of effective polymeric delivery vehicles.
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Chapter 1
Overview of dissertation
Pharmaceutical companies spend billions of dollars in research to bring a single therapeutic
compound to the market. The astronomical costs associated with drug development is often
attributed to the failure to translate compounds which were effective on the bench top to the
patient. For example, approximately only 10 % of all drugs entering Phase I clinical trials reach
approval status [1]. Fortunately, new therapies can effectively treat diseases without getting a
new drug approved by delivering the current therapeutic options more effectively.
The field of drug delivery focuses on improving the administration of existing drugs to
improve treatment efficacy in various diseases. While each disease offers a unique challenge,
a common goal of all delivery vehicles is to deliver the therapeutic agent to the disease site
while minimizing negative side effects on the patient. The development of an effective delivery
vehicle requires optimizing the loading and release of therapeutics and how the vehicle interacts
with the patient’s body. Broadly, my Ph.D. research has focused on developing new drug
delivery vehicles for cancer therapy and fundamentally understanding how current delivery
systems release their therapeutic payloads.
In this thesis, I first discuss the development of new delivery vehicles to deliver com-
binations of chemotherapeutic agents for the treatment of late stage cancer (Chapters 2-6).
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In Chapter 2, I provide background information on combination chemotherapy, the use of
nanomedicine in cancer, and the application of polymeric carriers to co-deliver multiple drugs.
In Chapter 3, I summarize the experimental methods used in this thesis, including in vitro and
in vivo assays, chemical synthesis, and material characterization techniques. In Chapter 4, I
screen through different drug pairs to identify synergistic drugs to deliver together, and study
how schedule impacts drug synergy. I proceed to discuss the development of two different
delivery systems: polymer drug conjugates (Chapter 5) and bi-phasic polymeric nanoparticles
(Chapter 6) for the co-delivery of synergistic chemotherapy drug pairs.
I then discuss the development of a new experimental, microfluidic technique which is
capable of measuring drug release in future research (Chapters 7-8). In Chapter 7, the mi-
crofluidic technique is characterized with respect to its ability to measure solute concentration
with high spatio-temporal resolution. In Chapter 8, the technique is used to measure solute
transport in PEG hydrogels to develop more accurate physical models for solute transport in
gels.
I conclude the thesis in Chapter 9 by summarizing the main findings of this research. I also
offer insight into future research pathways which can build upon the knowledge which was
gained in this dissertation.
Permissions and Attributions
1. Some content in Chapter 2 has been adapted from a review article which is currently in
review at Current Opinion in Colloid & Interface Science.
2. The content of Chapter 5 has been submitted to the Journal of Controlled Release for
review.
3. The content of Chapter 6 is the result of a collaboration with Jason Gregory from the
Lahann lab at the University of Michigan.
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4. The content of Chapter 7 has previously appeared in Lab on a Chip. The chapter is
adapted from Ref. [2] with permission from The Royal Society of Chemistry.
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Chapter 2
Combination chemotherapy and
nanomedicines in cancer
2.1 The use of combination chemotherapy
Cancer places a significant medical and financial burden on society; therefore, it continues
to remain an active area of scientific research. Being as two in every five people will be diag-
nosed with a form of invasive cancer during their lifetime, almost every individual is affected
by cancer in some manner [3]. Although mortality rates have been on a steady decline since
1990, additional treatment options must be developed to exacerbate this process as cancer re-
mains the second leading cause of death in the United States, following cardiovascular disease
[4].
While each cancer subtype has distinct characteristics, a unifying characteristic of all can-
cer cells is uncontrolled growth and proliferation [5]. The same general processes are typically
responsible for uncontrolled growth in cancer, even though cancer evolves from different onco-
genes [6]. Due to vast pathological and genetic differences when comparing different types
of cancer, many treatments have been developed, including surgical resection, chemotherapy,
4
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radiation, targeted therapies, and immunotherapies. The success of a given treatment is deter-
mined by its ability to eradicate tumor cells, prevent the relapse of future tumor cell prolifera-
tion, and minimize healthy tissue toxicity.
Systemic chemotherapy is commonly employed singularly or in combination with other
therapies for all types of cancer, due to its ability to target fast proliferating cells. However,
tumor cells are often unresponsive to single chemotherapy drugs. While some cells show resis-
tance to therapies at the onset of treatment, other cells, which are initially responsive to therapy,
develop increasing levels of resistance throughout the treatment [7]. Various mechanisms of
acquired drug resistance at both the cellular and tissue level have been identified in different
types of cancer and therapies [7]. Both upstream processes, such as over-expression of protein
pumps and overactive metabolic processes, and downstream processes, such as the inhibition
of apoptotic pathways and the activation of prosurvival signals, can limit the cytotoxicity of
accumulated drug [8, 9].
To overcome the development of drug resistance, combinations of chemotherapy drugs
with different cytotoxic mechanisms are commonly used in an attempt to improve therapeutic
outcome. Consistent throughout all types of cancer, combination chemotherapy is commonly
employed as front line therapy or as a last resort to treat late stage cancer subtypes [10, 11,
12, 13, 14]. Unfortunately, while patients tumors often respond to combination chemotherapy,
overall efficacy is limited due to increased toxicity associated with the combination treatment
[15].
2.2 Synergy in combination chemotherapy
The methodology behind using a combination of drugs is that drug combinations can over-
come various mechanisms of drug resistance and/or demonstrate enhanced antitumor activ-
ity compared to single drugs. This includes combining traditional small molecule therapeu-
5
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tics with other small molecule drugs or biologics [16]. In theory, combination chemotherapy
should allow oncologists to administer lower drug doses leading to less side effects [17]. Un-
fortunately, in the clinic, many combination treatments demonstrate increased toxicity with
minimal improvement in tumor reduction [15].
To reduce systemic toxicity, many researchers have identified drug pairs which work favor-
ably together in vitro. Drugs which enhance the activity of one another are commonly referred
to synergistic, while those which do not work favorably together are referred to as antagonistic
[18, 19, 20, 21]. Fundamentally, synergism will result when one drug enhances the perfor-
mance of another drug through some molecular mechanism. For example, if one inhibitor
enhances the binding of another inhibitor, the two drugs would be considered synergistic [22].
Although it would be convenient to be able to predict synergistic drug pairs in cancer simply
from mechanism alone, this is not possible due to the vast differences in cancer cell response
to chemotherapeutic agents [23]. For this reason, an empirical approach is commonly taken to
identify synergistic drug pairs. This approach is described in detail mathematically in Chapter
3. In vitro studies demonstrate that drug synergy is dependent upon many variables includ-
ing the molar ratio of the drugs in the combination [21]; therefore, precision is required in
translating these synergistic drug pairs effectively to the clinic.
In the clinic, doctors will typically administer each drug in a combination, similar to how
the individual drugs are administered with monotherapy. Monotherapy dosing and scheduling
is based upon the maximum tolerated dose (MTD) determined during preclinical and clinical
trials [24, 25]. Because dosing is optimized for single drugs, the potential benefits from using
the combination of drugs may not be realized due to sub-optimal drug dosing regimes. For
example, shown schematically in a cartoon in Fig. 2.1, lower drug doses can be effective when
the drug pair is administered in a synergistic ratio; however, a high drug dose must still be
administered if the drugs are given in an antagonistic ratio.
6
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Figure 2.1: Cartoon demonstrating how the therapeutic window can be increased by using a
synergistic drug pair
2.3 Scheduling in combination chemotherapy
Many variables contribute to whether a combination of drugs enhances antitumor activity,
including the dose of each drug and the schedule in which the drugs are administered. The
majority of combination studies examine the effect of drug ratio on synergy during concurrent
drug exposure [21], while less in vitro studies study the impact of drug exposure schedule on
synergy. Fundamental cancer cell biology is now presented, placing an emphasis on why drug
administration schedule should significantly impact the efficacy of a given treatment. Further-
more, examples of in vitro studies which have studied scheduling in combination chemotherapy
are presented.
2.3.1 Time-dependent processes in combination chemotherapy
While drug schedule is often overlooked, many time dependent cellular processes exist
which impact cellular response to different drug schedules. In particular, the progression of the
7
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cell cycle, induction of cell death, and development of drug resistance are all processes that are
critical to the efficacy of a given treatment. The time scales of these processes occur on the
order of minutes to days, which give further motivation that drug scheduling is critical to the
success of a given treatment.
Cell cycle progression and cell death
Cell growth, replication, and death are all highly regulated processes controlled by the
progression of the cell cycle. The cell cycle consists of four stages and the progression is
regulated by a family of proteins, cyclin dependent kinases (CDKs). Two primary checkpoints
are in place in the cell cycle: between the first gap phase (G1) and DNA synthesis stage (S) and
between the second gap phase (G2) and mitotic stage (M). Typically in cancer, abnormalities in
the CDKs, cyclins, CDK activating enzymes, CDK inhibitors, and/or CDK substrates disrupt
these regulated processes and induce uncontrolled cell division [26].
Many toxic cancer drugs target specific stages of the cell cycle. In the body, healthy, so-
matic cells are usually in a reversible quiescent state (G0 phase) until exposure to mitogenic
signals trigger reentry into the cell cycle and cell division [6]. Therefore, cancer drugs com-
monly target cells in the S or M phase to reduce side effects because a higher fraction of cancer
cells are in these stages as compared to healthy cells [27].
In order for a chemotherapy drug to be effective, it must disrupt the uncontrolled prolifera-
tion, which requires either inducing cellular senescence or cell death. On a fundamental level,
many different molecular pathways evoking cell death have been identified including necrosis,
intrinsic and extrinsic apoptosis, and autophagic induced cell death [28]. Typically, the effec-
tiveness of chemotherapy can be correlated to the ability to induce apoptosis in cancer cells;
however, evading apoptosis is one of the main hallmarks of a cancer cell [29, 5]. The molecules
involved in regulating apoptosis are often also involved in the progression of the cell cycle and
temporally cycling [30]; therefore, the timing in which a drug is given can have a significant
8
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impact on outcome.
Development of cancer drug resistance
The success of chemotherapy is often dependent upon avoiding the development of drug
resistance and targeting cells which are already resistant to specific therapeutics. Often times,
the mechanisms involved with drug resistance include complicated regulatory networks with
nonlinear dynamics; therefore, drug scheduling also plays a significant role in the development
of drug resistance and efficacy of treating resistant cancer cells [31, 32].
For example, tumor cells have shown the ability to acquire drug resistance though the ex-
pression of membrane drug pumps. Specifically, the overexpression of ATP-dependent trans-
porters is known to induce multidrug resistance in cancer cells by increasing the efflux of
small, hydrophobic molecules, such as doxorubicin [8]. One common member of the family, P-
glycoprotein 1 (P-gp), is commonly associated with multidrug resistance and is responsible for
cellular resistance to doxorubicin treatment [33]. Acute exposure to doxorubicin increase the
expression of P-gp both in vitro and in vivo [34, 35, 36]. The overexpression is dependent upon
both drug concentration and exposure time [37]. After drug exposure, P-gp expression either
returns to an initial state to reestablish homeostasis or maintains the elevated levels [35, 36].
Due to the complicated interactions between P-gp expression and DOX exposure, it is likely
that schedule will have a significant impact on clinical efficacy for this drug-cell pair.
2.3.2 In vitro studies examining the effect of drug schedule on synergy
When considering cellular response to a drug, a temporal profile of various signaling
molecules develop which then become responsible for carrying out different cellular tasks,
such as promoting cell death or evoking the induction of drug resistance [38]. In cancer, these
processes often behave in an uncontrolled and unpredictable manner. Although it seems plau-
9
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sible that there exists an optimal sequence in which a drug or pair of drugs can be given, this
sequence is not something that can be predicted a priori; therefore, in vitro experiments provide
a useful tool to understand how cancer cells respond to various therapies.
Many in vitro studies have demonstrated that the synergy of a chemotherapy drug combi-
nation is dependent upon drug administration schedule (Table 2.1). For each drug pair and cell
line, sequential drug exposure (Drug A⇒ Drug B versus Drug B ⇒ Drug A) was compared
to concurrent drug exposure. Many times, the sequential exposure of one drug (hours to days)
prior to another drug significantly enhanced the activity of the drug combination [39, 40, 41].
In addition, some drugs which were antagonistic when given concurrently, were found to be
synergistic when given sequentially, motivating the importance of understanding drug schedul-
ing in combination treatment. Many common mechanisms were found to be responsible for the
schedule-dependent synergy, typically involving apoptosis [32, 42, 43] or a cell cycle mediated
effect [44, 45].
While many of these studies show mechanistically that schedule impacts drug synergy in
vitro, the majority fail to discuss how this synergy translates to in vivo conditions. Furthermore,
a discussion on how the synergistic schedules can be translated to a clinical setting is required
to fully understand the utility of the drug combination. An emphasis on both identifying syn-
ergistic drug pairs and designing therapies to translate this synergy to the clinic is a necessity
to take advantage of the benefits of using combinations of chemotherapeutic agents.
2.4 Drug delivery vehicles in oncology
While effective for various cancers and stages, traditional chemotherapy is severely limited
by systemic toxicity. The majority of chemotherapy drugs are administered intravenously,
and then distribute throughout the body, with minimal preference to accumulate at the tumor
site. Recent advances in the fields of drug delivery and nanotechnology have made it possible
10
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Table 2.1: Examples of in vitro tumor cell studies identifying schedule dependent combination synergy
First author, year Cancer Synergistic schedule Proposed mechanism
Amadori, 1996[39] Breast Doxorubicin (4h) ⇒ Pa-
clitaxel (24 h)
-
Budman, 2000[46] Breast Vinorelbine (48-72 h) ⇒
Paclitaxel
-
Cheng, 2011[44] Lung Paclitaxel (24 h) ⇒ Gefi-
tinib (48 h)
Increase in pEGFR in-
duced by paclitaxel inhib-
ited by Gefitinib
Chou, 1996[40] Breast Edatrexate (3 h)⇒ Taxol -
Kano, 1998[47] Breast, ovar-
ian, colon,
and lung
Paclitaxel (24 h) ⇒
Methotrexate (24 h)
-
Lee, 2012[32] Breast Erlotinib (24 h) ⇒ Dox-
orubicin
Reactivation of extrinsic
apoptotic pathway by in-
hibition of EGFR
McHugh, 2007[48] Bladder Lapatinib (24 h)⇒ Gem-
citabine or Cisplatin (24
h)
-
Oliveras-Ferraros, 2008[42] Breast Paclitaxel (24 h)⇒ Gem-
citabine (48 h)
Increase in Bcl-2 family,
inducing more apoptosis
Perez, 1993[41] Lung Edatrexate (3 h) ⇒ Cis-
platin
-
Takahashi, 2002[45] Breast Paclitaxel (24 h) ⇒
Ecteinascidin 743 (72 h)
Accumulation into G1
phase after first exposure,
increasing toxicity of 2nd
drug
Tanaka, 2005[43] Gastric,
tongue
Pactlitaxel (24 h) ⇒ Ox-
aliplatin
Induction of G2 arrest,
followed by increase in
apoptosis in sub G2 phase
to deliver chemotherapeutic agents within a nano-sized delivery vehicle which preferentially
delivers more drug to the tumor site. In addition, more recently, there has been a significant
focus on delivering multiple therapeutics in a single delivery vehicle to increase the potency of
the delivered therapeutic payload.
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2.4.1 Nanomedicines in oncology
In 1995, the first FDA approved nanodrug (Doxil R©) was approved for the treatment of
AIDS-related Kaposis sarcoma [49]. Doxil R©, which is a liposomal formulation of doxoru-
bicin, accumulated more at the tumor site and was more tolerable in patients than free doxoru-
bicin. Based on early success, Doxil R© has subsequently been approved to treat other advanced
malignancies.
Since the early development of Doxil R©, researchers have developed many other nano-sized
delivery vehicles to carry chemotherapeutic agents (Fig. 2.2). The delivery vehicles consist of
both polymeric, lipid, and inorganic material scaffolds, and drugs are both physically entrapped
within the vehicles or chemically conjugated. While each delivery vehicle is unique, many of
the nano-sized delivery systems distribute in the body and are cleared through similar clearance
pathways. In order for a delivery vehicle to be effective, it needs to both circulate for extended
periods of time and to target tumor tissue either through passive or active mechanisms.
Contrary to small molecule therapeutics, most nano-sized delivery vehicles are too large
to be cleared renally because the glomerular epithelium cutoff is approximately 4 to 6 nm.
Therefore, the majority of nanoparticles are cleared by the reticuloendothelial system (RES).
By avoiding fast uptake by the RES, particles can circulate for extended periods of time in
the body, giving more opportunity for the particles to accumulate at the tumor site. Strategies
to avoid RES clearance include coating particle surfaces with polyethylene glycol (PEG) or
hyaluronic acid (HA) [51] or modifying physical properties such as size, shape, and flexibility
[52, 53].
Delivery vehicles which circulate for extended periods of time have the ability to accumu-
late in solid tumors passively through the Enhanced Permeability and Retention (EPR) effect
[54, 55]. The tumor vasculature in solid tumors is highly irregular leading to large gaps between
the endothelial cells lining the tumor vasculature and poor lymphatic drainage due to uniform
12
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Figure 2.2: Types of nano-sized delivery vehicles used in oncology. Reprinted from [50],
with permission from Elsevier.
interstitial fluid pressure throughout the tumor and the lack of lymphatic vessels (Fig. 2.3).
Due to these irregularities, macromolecules which are larger than 40 kDa, tend to accumulate
and retain in the tumor [56]. While utilizing the EPR effect has proven to be an effective way in
treating subcutaneous mouse models, many of the nano delivery vehicles which have entered
human clinical trials have been ineffective [57, 58]. The discrepancy in treatment efficacy in
murine cancer models to human cancers is largely believed to be due to significant differences
in tumor vasculature. The use of more advanced murine cancer models and diagnostic tools to
identify human patients which the EPR effect is effective are solutions to this serious issue.
In addition to passive targeting, many drug delivery systems utilize active targeting to
increase the delivery of drugs to the tumor. In many cancers, the cancer cells or local tu-
mor environment overexpress various extracellular receptors which provide a target to bind
to. Nano-sized delivery vehicles have been coated with small molecules, such as sugars, or
13
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macromolecules, such as antibodies, aptamers, peptides, and oligonucleotides, which bind to
the overexpressed receptors with great selectivity [50]. Most notably, antibody drug conjugates
(ADC), which consist of a monoclonal antibody conjugated to a cytotoxic drug, have been eval-
uated in the clinic over the past few decades, with a few recent products improving treatment
efficacy over standard care [59]. Unfortunately, many of the targeted therapies are still limited
by off-site toxicity. In addition, a recent review on nanoparticle delivery has shown that active
targeting mechanisms only improved the average delivery of nanoparticles to murine, solid
tumors from 0.6 % to 0.9 % of the injected nanoparticle dose [57].
Figure 2.3: (A) Cartoon schematic demonstrating nanoparticle delivery to solid tumors uti-
lizing the EPR effect. (B) Active targeting of nanoparticles to tumor cells (1) or to tumor
vasculature (2). Reprinted from [58], with permission from Elsevier.
Regardless of how the delivery vehicle reaches the tumor site, the therapeutic payload needs
to be released to be effective. Most systems which have been evaluated in the clinic release
14
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drugs through passive mechanisms, such as the degradation of the delivery vehicle or hydrol-
ysis of chemical bonds. Many vehicle designs take advantage of the tumor microenvironment,
consisting of a slightly acidic pH, abundance of specific enzymes, and hypoxic conditions, to
release drugs more quickly at the tumor site. More recently, there has been significant effort in
designing systems which release their payloads when triggered externally, typically using light
or ultrasound [50, 60].
After the initial approval of Doxil R© 20 years ago, there has been a significant amount of
research devoted to developing new nanomedicines and optimizing the biodistribution and drug
release of these vehicles. Unfortunately, many of the deliver systems which initially showed
promise in preclinical trials, were ineffective in clinical trial for reasons just discussed. More
recently, various nanomedicines have started to perform well in clinical trials, and there are
currently over 12 products approved for cancer treatment [61]. For example, liposomes, anti-
body drug conjugates (such as Kadcyla), and polymeric nanoparticles (such as Abraxane) have
all been approved for various malignancies. From the accumulation of clinical trials, it is clear
that using delivery systems can drastically alter the biodistribution of chemotherapeutics lead-
ing to less systemic toxicity, and more research is currently underway to continue to unleash
the full therapeutic potential of nanomedicine. One area of research which is sparking a lot of
interest is using delivery systems to deliver multiple therapeutics, which will now be discussed.
2.4.2 Use of delivery vehicles to deliver multiple chemotherapy drugs
Many drug pairs which are identified as effective (and often synergistic) in pre-clinical
studies will be ineffective in the clinic. The failure in translation can be attributed to many vari-
ables, such as the inability to deliver both drugs simultaneously to the tumor site. Chemother-
apy drugs have vastly different chemical and physical properties, and, therefore, are cleared
through different pathways with different pharmacokinetics. It is generally believed that if
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both drugs can circulate together, translation of drug combination from in vitro assays to the
clinic can be significantly improved. Therefore, many nano-scaled delivery systems have been
designed to carry combinations of chemotherapeutic agents directly to the tumor site (Fig. 2.4).
Figure 2.4: Cartoon demonstrating how nanoparticles can be used to deliver combinations of
chemotherapeutic agents together throughout the body. Reprinted from [62], with permission
from Elsevier.
In an attempt to increase the overall efficacy and reduce toxicity, drug delivery systems
(DDS) carrying various combinations of chemotherapeutic agents have been engineered and
tested [63, 62]. Liposomes, polymeric nanoparticles, inorganic nanoparticles, polymeric mi-
celles, and polymer drug conjugates (PDCs) designed to carry combinations of chemotherapy
agents have shown better efficacy in preclinical models compared to free drug combinations.
Furthermore, VYXEOS (CPX-351), a liposomal formulation carrying daunorubicin and cy-
tarabine, significantly extended patient survival over the standard care in a phase III clinical
trial while treating secondary acute myeloid leukemia (AML).
When considering drug delivery in combination therapy, the ability to deliver a combination
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of drugs at specific ratios is only half of the challenge because most synergistic drug pairs
exhibit schedule dependent synergy. Typically, drug pairs are identified as synergistic when
given concurrently; however, many drug pairs need to be sequenced correctly to exhibit synergy
as discussed in a previous section. Many nanocarriers have been designed to deliver specific
ratios of multiple drugs or to deliver drugs at specified times; however, the ability to control
both these features in the same vehicle offer a significant synthetic and design challenge [64].
A few nano-sized delivery vehicles have been synthesized which control the relative release
rate of multiple therapeutics by incorporating each drug into distinct regions in the particle. For
example, particle systems which incorporate one drug into an outer particle shell and another
drug into the particle core, can release the drugs at distinctly, different rates. Multiple studies
have used this core-shell design methodology to release drugs with different release kinetics to
improve the efficacy of a given drug pair [65, 66, 67, 68, 69]. While these studies demonstrate
the potential benefits of using core-shell particles to stagger the release of multiple drugs, the
particle design requires drastically changing particle structure to change release kinetics. In
addition, the loading and release of each drug is dependent upon the physical properties of the
drug, limiting the possible release profiles for any given particle design. More research into the
development of combination delivery vehicles which control release rates with external stimuli
or chemical linkers will help develop particle systems with more control over relative release
kinetics.
2.5 Polymer drug conjugates
Of all systems engineered thus far to deliver chemotherapy agents, PDCs are unique and
offer multiple advantages. Instead of physical encapsulation, drugs are chemically conjugated
to a polymer, and the drug ratio and subsequent release rates are governed by the chemistry
used to incorporate the drugs. While only a few combination PDCs have entered the clinic,
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the success of single agent PDCs in clinical trials, most notably the ability to decrease toxic-
ity, give rise to further motivation in continuing the development of PDC-based combination
chemotherapy [70, 71, 72, 73, 74, 75].
2.5.1 Single drug polymer drug conjugates in clinical trials
Helmut Ringsdorf first proposed the idea of linking drugs to a polymeric carrier via a co-
valent bond in 1975 [76]. Since then, a variety of polymeric-based drug delivery systems have
been engineered to deliver therapeutic agents and studied extensively in vivo [77, 78, 79, 80,
81, 82]. When compared to traditional small molecule therapeutics, polymer-drug conjugates
(PDCs) can improve the drugs solubility in water, protect it from systemic degradation, and
increase drug circulation time. This increases the drugs bioavailability at the desired site of
action, thereby reducing the dose required to elicit the desired outcome.
A wide range of natural and synthetic water-soluble polymers, which are biocompatible,
have been synthesized to deliver drugs. While each polymer drug system has its own physical
characteristics, a few general trends have been observed in the field. For example, studies have
shown that polymers with a higher molecular weight tend to circulate longer in the plasma
due to reduced renal clearance rates, and can accumulate higher at the tumor [83, 84]. On the
contrary, polymer architecture and structure has shown minimal effect on tumor extravasation
[85]. The polymer drug conjugates which have been evaluated in the clinic are now discussed
and summarized in Table 2.2.
HPMA copolymer-drug conjugates
Although a synthetic polymer, N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer
is the most versatile and greatly explored polymer used in PDCs. HPMA is highly soluble
in water, nontoxic, non-immunogenic, and capable of circulating in the blood for extended
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periods due to non-adsorption of plasma proteins [86]. The HPMA copolymer is generally
synthesized via free radical polymerization of co-monomers HPMA and methacrylated (MA)-
peptidyl-nitrophenylester (ONp). Although non-biodegradable, HPMA-drug conjugates with
a molecular weight (MW) less than 40 kDA can be eliminated from the body via renal filtra-
tion. Further, multi-block degradable HPMA conjugates have been designed to allow for larger
constructs to be administered systemically and still be cleared [87].
Various HPMA products have been evaluated in clinical trials, including conjugates car-
rying doxorubicin (DOX), paclitaxel (PTX), camptothecin (CPT), and DACHPt (oxaliplatin
parent complex) [73, 75, 88, 89]. In all of the trials, 20 to 30 kDa HPMA copolymers were
used with the peptide cleavable linker GFLG or acid labile linkers. In addition, a targeting lig-
and was also evaluated by conjugating both galactosamine and DOX to HPMA (PK2) [90]. The
majority of the phase I and II clinical trials reported acceptable toxicity with partial responses
during treatment of various cancers. All conjugates reported improved drug bioavailability and
tolerable toxicity profiles, and the conjugate carrying DACHPt (ProLindac) has shown very
promising clinical results. Phase I/II clinical evaluation of ProLindac in patients with recurrent
ovarian cancer demonstrated an excellent safety profile and antitumor efficacy. Subsequently,
a multicenter-based evaluation of ProLindac in combination with Paclitaxel (PTX) is being
pursued in Europe for treatment of late stage ovarian cancer [91].
Polysaccharide-drug conjugates
Polysaccharide-based systems are highly attractive due to their biocompatibility, biodegrad-
ability, and relatively low synthesis costs. Polysaccharides are highly soluble in water and have
various functional groups to conjugate drugs. Due to their ability to be degraded naturally,
higher MW conjugates can be administered to enhance plasma retention times. In addition,
certain polysaccharides are capable of specifically binding to cancer cells, such as hyaluronic
acid (HA) which binds to CD44 (a cell surface receptor that is highly expressed on cancer
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cells).
Polysaccharide-drug conjugates that have entered clinical trials were primarily based upon
hyaluronic acid (HA), dextran (DEX), and cyclodextrin. Many of these conjugates, includ-
ing AD-70 (oxDEX-DOX), DE-310 (cmDEX-exatecan), and MEN 4901/T-0128 (cmDEX-T-
2513) showed excellent response rates, but severe toxicity limited the treatments [92, 93, 94].
A paclitaxel conjugate with HA administered with intravesical therapy showed excellent effi-
cacy while treating bladder cancer locally [95]. In addition, a -Cyclodextrin-PEG copolymer
with CPT (CRLX-101) is currently being evaluated for treating various types of cancers in
phase 2 trials due to promising phase 1 results [72].
PEG-drug conjugates
Poly (ethylene glycol) (PEG) is an FDA approved commercial polymer widely used for
biological applications. Due to its hydrophilic nature and reduced uptake by the reticuloen-
dothelial system (RES), PEG can enhance the plasma half-life (t1/2) and therapeutic index
of drugs or proteins conjugated to its backbone. PEG conjugates with MW in the range of
20-50 kDa can avoid renal elimination, and nanoparticles formed from PEG with MW (2-5
kDa) circulate in the blood longer and avoid hepatic clearance [96]. In the clinic, drugs have
been conjugated directly to the ends of single and multi-arm PEG and to block-copolymers
containing PEG, which typically self-assemble into micelles.
PEG conjugates of CPT and active metabolites of CPT including Irinotecan (CPT-11) and
SN38 were evaluated in clinical trials [97, 98, 99]. In PROTHECAN (PEG-CPT), CPT is
conjugated to both ends of PEG with glycine spacers, while in EZN-2208 (PEG-SN38) and
NKTR-102 (PEG-CPT-11), four drug molecules are conjugated to 4-arm PEG polymers. In all
of the clinical studies, conjugation to PEG significantly increased drug bioavailability, and the
PEG-drug constructs showed partial responses in the trials.
Various ampiphilic block copolymers of PEG-polypeptides were also tested in the clinical
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setting. DOX (NK911) and epirubicin (EPI) (NC-6300) were conjugated to PEG-b-poly(aspartic
acid) which self-assemble into 40 nm and 60 nm micelles, respectively [100, 101]. Similarly,
SN38 was conjugated to PEG-b-poly(l-glutamic acid) with an ester bond, forming 20 nm mi-
celles (NK012) [102]. In addition, the platinum drugs Cisplatin (CIS) and DACHPt were con-
jugated to PEG-b-poly(l-glutamic acid) with Pt coordination linkers (NC6004 and NC4016,
respectively) forming micelles of approximately 30 nm [70, 103]. Having demonstrated good
tolerability and acceptable efficacy in early clinical studies, NC6004 is now being tested in
combination with gemcitabine (GEM) for the treatment of locally advanced or metastatic pan-
creatic cancer in a phase 3 study.
PG-drug Conjugates
Poly(α , L-glutamic acid) (PG) is a naturally occurring polypeptide composed of repeating
units of L-glutamic acid. The polymer is highly soluble in water due to a negative charge that
exists at neutral pH on the pendent free carboxyl group in each repeating unit of glutamic acid.
PG is biocompatible and can undergo lysosomal degradation. It is primarily cleared via renal
pathways with limited involvement of the reticuloendothelial system.
The poorly soluble drugs PTX and CPT have been conjugated to PG and evaluated in
clinical trials, as XYOTAX and CT-2106, respectively [?, 104, 105]. PTX and CPT were
conjugated to 39 kDa and 49 kDa PG, respectively, with an ester bond. Both drugs showed a
significant increase in plasma half life upon conjugation with better tolerability than the single
drugs.
2.5.2 Use of polymer drug conjugates in combination chemotherapy
Tumor cells often develop resistance to single drug therapy, minimizing treatment efficacy
of polymer therapeutics carrying a single drug. To more effectively inhibit tumor growth,
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Table 2.2: Single drug polymer drug conjugates evaluated in the clinic
Conjugate Name Polymer-Drug MW (kDa) Clinical trials (cancer, phase)
HPMA-drug conjugates
PK1 [11,13] HPMA-DOX 30 Non small cell lung, breast cancers
(Phase III)
PK2 [31] HPMA-DOX-
galactosamine
25 Hepatocellular carcinoma (Phase I/II)
PNU-166945 [29] HPMA-PTX 25 Refractory solid tumors (Phase I)
PNU-166148 [30] HPMA-CPT 18 Gastric and gastroesophageal tumors
(Phase I)
AP-5346 [15] HPMA-DACHPt 25 Ovarian cancer (Phase I/II)
Polysaccharide-drug conjugates
ONCOFID-P-B
[36]
HA-PTX 200 Bladder carcinoma refractory to BCG
(Phase I)
AD-70 [33] oxDEX-DOX 70 Various advanced cancers (Phase I)
DE-310 [34] cmDEX-exatecan 360 Metastatic adenocarcinoma (Phase I)
MEN 4901/T-0128
[35]
cmDEX-T-2513 130
CRLX101, IT-101
[12]
-Cyclodextrin-
PEG-CPT
57 Advanced tumors (Phase I)
PEG-drug conjugates
PROTHECAN [38] PEG-CPT 40 Advanced solid malignancies (Phase I)
EZN-2208 [39] PEG-SN38 40 Metastatic colorectal and breast can-
cers and pediatric cancer (Phase II)
NKTR-102 [40] PEG-Irinotecan 20 Ovarian, breast, colorectal, and cervi-
cal (Phase II)
NK911 [41] PEG-b-PASA-
DOX
16 Metastatic pancreatic cancer (Phase II)
NC-6300 [42] PEG-b-PASA-EPI 20 Advanced or metastatic solid tumors
(Phase I)
NK012 [43] PEG-b-PG-SN38 19 Small cell lung cancer (Phase II)
NC-6004 [10] PEG-b-PG-CIS 26 Locally advanced or metastatic pancre-
atic cancer (Phase III)
NC-4016 [44] PEG-b-PG-
DACHPt
18 Advanced solid tumors or lymphoma
(Phase I)
PG-drug conjugates
XYOTAX, CT-
2103 [45,47]
PG-PTX 39 Stage III or IV ovarian or primary peri-
toneal cancer (Phase II)
CT-2106 [46] PG-CPT 49 Advanced solid malignancies (Phase I)
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treatments can be designed to use PDCs to deliver a combination of chemotherapeutic agents.
As originally discussed in the review by Greco et al. [106], there are many ways to incorporate
PDCs into a combination chemotherapy platform. Most simply, two single drug PDCs can be
administered simultaneously or at different time points. However, it may be advantageous for
the drugs to circulate together, in which case a single delivery vehicle should be used. This
vehicle can be a self-assembled structure of a single drug PDC with an adsorbed drug, a self-
assembled structure of multiple single drug PDCs, or a polymer with multiple drugs conjugated
to the same polymer backbone. Examples of these differences are shown schematically in Fig.
2.5.
Figure 2.5: Cartoon schematic of the physical structure of polymer drug conjugates (PDCs)
used to deliver combinations of chemotherapeutic agents.
Combination of drug pairs
Many PDC systems have been designed to deliver combinations of synergistic chemother-
apeutic agents for various cancers. Block copolymers of PEG, which all self assemble into
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micelles, have delivered DACHPt/EPI [107], CIS/DOX [108], CIS/PTX [109], and CPT/DOX
[110] for treating advanced gastric cancer, hepatocellular carcinoma, cervical cancer, and breast
cancer, respectively. The polysaccharides HA [111] and dextran [112] have also co-delivered
CPT/DOX and HA has co-delivered CIS/DOX [113] for treatment of breast cancer. PG [114]
and a pegylated polyglycerol dendrimer [115] have carried PTX/DOX for treatment of breast
cancer. HPMA has also been used to deliver DOX/GEM [116] and DOX/DTX [117] for treat-
ment of prostate and lymphoma, respectively.
The majority of these combination PDC systems demonstrate less toxicity and improved
tumor growth inhibition compared to delivering the free drug combinations in vivo. Of the
studies which report biodistribution, significantly more of each drug accumulates at the tumor
site when delivered with a PDC compared to free drug administration. In addition, the com-
bination conjugates show improved efficacy compared to control conjugates carrying single
drugs, demonstrating the importance of using synergistic drug pairs.
In addition to delivering synergistic drug pairs, PDCs can often overcome the resistance
typically associated with traditional chemotherapy. Drug resistance can be specific to a sin-
gle drug, or to a large class of chemotherapeutics, often due to the over-expression of P-
glycoprotein (P-gp) pumps which pump out small molecule drugs. Conjugation to a poly-
mer can eliminate drug efflux from P-gp pumps, resulting in improved efficacy in many drug
resistant cells.
Sensitivity to a specific drug can also be restored by delivering another drug simultaneously
with the PDC which re-sensitizes the cell. Taxane-resistant prostate tumor cells have been ef-
fectively treated with an HPMA conjugate carrying DTX with cyclopamine [118] and PEG
block copolymers carrying PTX with cyclopamine [119]. DOX resistant cancer cells have
been treated with a xyloglucan conjugate carrying DOX and mitomycin C [120], an HPMA
conjugate delivering DOX with P-gp inhibitors [121], and a polystyrene block copolymer car-
rying DOX and the P-gp inhibitor disulfiram [122].
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Polymer carriers can also carry therapeutics which improve tumor targeting. The clinical
product PK2 (HPMA-DOX-galactosamine), used galactosamine to specifically target the PDC
to liver cells. Similarly, alendronate has been combined with PTX to target bone metastases
in breast cancer using both an HPMA conjugate [123, 124] and a PEG dendrimer construct
[125, 126]. In addition, chemotherapeutic agents can be combined with anti-vasculature drugs
to simultaneously inhibit cancer cell growth and prevent the tumor from getting nutrients. For
example, Wang et al. demonstrated the usefulness of forming a combination PDC which targets
the tumor vasculature along with the tumor cells by using a PEG block copolymer to co-deliver
PTX with Combretastin A4 [81]. There are also many examples of PDCs which deliver a
nucleic acid, protein, or peptide with a small molecule drug to improve cancer cell sensitivity
or carrier targeting [127, 128].
Physical combination compared to dual construct
For each PDC system, a critical parameter to address is whether or not it is satisfactory to
physically mix together single drug PDCs, or if further therapeutic benefits can be obtained by
incorporating multiple therapeutics into the same delivery vehicle. While a combined vehicle
ensures that both drugs distribute similarly in the body, physically combining single drug PDCs
allows for more flexibility in changing the drug ratio and schedule of administration of each
drug.
Many studies have shown that using a combination conjugate is more effective than the
physical mixture of single drug PDCs because both drugs are delivered simultaneously to the
tumor site. For example, Makovsky et al. clearly demonstrated the improved therapeutic
benefits of the dual construct PG-PTX-DOX compared to the physical mixture of PG-PTX and
PG-DOX [114]. Furthermore, other studies have demonstrated the importance of controlling
drug ratio on polymer backbone to maximize synergy and minimize administration dose, using
the Chou-Talalay method [108, 111, 112, 23]. Interestingly, the optimal drug ratio can change
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upon conjugation to a polymeric carrier due to new drug availability kinetics. For example,
Camacho et al. have shown that the internalization of CPT and DOX is drastically different
after conjugation to HA, leading to differences in sub-cellular concentrations of each drug
[111].
On the contrary, a significant benefit of physically mixing together single drug PDCs is the
ability to simply optimize the administration sequence of the carriers. For example, Zhang et
al. demonstrated that giving an HPMA conjugate carrying GEM prior to an HPMA conjugate
carrying PTX was more effective than other administration sequences [129]. Similarly, another
report demonstrated that giving an HPMA-GEM conjugate prior to an HPMA-DACHPt con-
jugate was more effective than other schedules at inhibiting ovarian cancer cell growth in vitro
[130].
Vehicle structure
While there are a plethora of studies which show the benefits of using a polymeric carrier to
deliver a combination of drugs compared to free drug administration, few studies compare how
effective the particular carrier is to other possible carriers. Variables such as vehicle structure
(size, drug loading, etc.) and polymer properties (molecular weight, architecture, etc.) will
play a role in affecting the performance in vivo. A few studies have explored how the physical
architecture of a PDC with multiple drugs affects its efficacy in vitro and in vivo.
In one study, two combination PDCs, both carrying DOX and PTX were compared [115]. A
dendritic conjugate (PGlycerol-PTX-DOX-PEG) was similar in efficacy to the physical com-
bination of PGlycerol-PTX-PEG and PGlycerol-DOX-PEG, while the linear conjugate (PG-
PTX-DOX) was much more effective than the physical combination of PG-PTX and PG-DOX.
The authors hypothesize that the individual linear PDCs have different pharmacokinetic pro-
files, while the individual dendritic PDCs distribute similarly allowing for both drugs to reach
the tumor site at the same time as with the combination conjugate.
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In another report, two HPMA conjugates carrying DOX and DTX with different archi-
tectures were directly compared [117]. DOX and DTX were conjugated to both linear HPMA
(∼25 kDa) and degradable, dendritic HPMA (∼250 kDa) with a hydrazone bond and levulinate
linker, respectively. In a subcutaneous tumor model, both linear P-DOX and dendritic P-DOX
were extremely effective at inhibiting tumor growth. Interestingly, the physical combination of
linear PDCs was slightly more effective than linear P-DOX, but the physical combination of
dendritic PDCs was significantly less effective than dendritic P-DOX. Less dendritic P-DOX
accumulates at the tumor site when administered with dendritic P-DTX, giving insight into the
additive behavior between the dendritic PDCs in vivo. The authors hypothesize that the nor-
malization of the blood vessels at the tumor site after DTX exposure, makes it more difficult
for dendritic P-DOX (as opposed to linear P-DOX which is smaller) to accumulate at the tumor
site with the EPR effect. This study clearly demonstrates that the interactions between drugs is
not just limited to tumor cell toxicity but also to tumor accumulation.
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Experimental methods
3.1 In vitro cell assays
All cell lines were cultured in a humidified incubator maintained at 37 ◦C and 5% CO2.
MDA-MB-231 and 4T1 cells were cultured in RPMI-1640 media supplemented with 10 %
FBS and 0.5 % Pen Strep. BT-474 cells were cultured in Hybricare media supplemented with
10 % FBS and 1 % Pen Strep. MCF-10a cells were cultured in MEBM media supplemented
with hydrocortisone, hEGF, insulin, BPBPE, 100 ng/mL cholera toxin, and 1 % Pen Strep.
3.1.1 Toxicity
The toxicity of all drug formulations was measured with the MTT assay. Cells (5 x 103
MDA-MB-231, 5 x 102 4T1, 1 x 104 BT-474, or 1 x 104 MCF-10a) were seeded in 100 µL of
media into the wells of a 96 well plate and allowed to adhere overnight. Media was aspirated
and replaced with drug formulations and cells were incubated with the drug solutions for 72 h
(unless specified otherwise). If a shorter drug exposure, or delayed drug exposure was required,
drug formulations were added and/or removed at the time points specified. After 72 h, all drug
formulations were replaced with an MTT solution in media (0.5 mg/mL) and incubated for
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3.5-4 h. The MTT solution was then aspirated and replaced with DMSO, and the plates were
shaken for 30 min. Finally, cellular viability was measured by reading the absorbance of each
well at 570 nm (Tecan Infinite M200 Pro).
Dose response curves were fit to each drug formulation with the median effect model [21].
For combination treatment, synergy was quantified with the combination index (CI), described
in detail in an upcoming section. Error bars for the combination index were calculated by
propagating the confidence intervals from the individual drug fits and the error in toxicity for
the combination treatment. When calculating the combination index, single drug dose response
curves were used with the identical schedule as given in the combination treatment.
3.1.2 Cell cycle analysis
Cell cycle distribution was determined after exposure to drug formulations with propidium
iodide (PI). MDA-MB-231 or BT-474 cells were seeded into T25 flasks (7.5 mL; 1 x 105
cells/mL) and allowed to adhere overnight. Media was replaced with drug solutions, and cells
were incubated with the drugs for 1 d, 2 d, or 3 d. At the endpoint, adherent and floating cells
were collected with trypsin and centrifugation. Cells were washed 2x in PBS (5 mL) and then
fixed by slowly adding 70 % ethanol (5 mL) with vortexing. Cells were maintained at 4 ◦C for
at least 1 d and then washed again 2x with PBS (5 mL). The cells were then suspended into
a PBS solution (500 µL) containing RNase A (100 µg/mL) and Tween 20 (0.01 vol. %). PI
(5 µL) was added and the cells were gently vortexed and incubated in the dark at 25 ◦C for
30 min. After dye incubation, cells were placed on ice until analysis. Fluorescence of each
cell was immediately quantified with flow cytometry using a Becton Dickinson FACSAria cell
sorter (Franklin Lakes, NJ, USA) with a 633 nm laser with 660 PMT.
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3.1.3 Apoptosis analysis
Apoptosis activity was determined by measuring Caspase 3 activity. Caspase 3 activity was
determined using the EnzChek Caspase-3 assay kit. Briefly, cells were seeded into T25 flasks
(7.5 mL; 1x105 cells/mL) and allowed to adhere overnight. Following incubation with drug
formulations, floating cells and adherent cells were collected with trypsin and centrifugation.
The cells were washed 1x in PBS, and then lysed in 75 µL of 1x lysis buffer for 30 min on
ice. Lysed cells were then centrifuged at 5000 rpm for 5 min to remove cell debris, and the
supernatant was collected. Caspase activity was quantified by mixing 50 µL of the supernatant
with 50 µL of the 2x working solution containing the substrate Z-DEVD-AMC and incubated
for 30 min. The fluorescence of each well was then measured with a Tecan Plate Reader
(342/441 nm) for 30 min, and total caspase activity was calculated with respect to an AMC
standard curve.
Caspase activity was then normalized to the total protein content, using the micro BCA
assay (Thermo Scientific). Briefly, 15 µL of the leftover supernatant was diluted with 135
µL of DI water and incubated with 150 µL of the BCA solution for 1.5 h at 37 ◦C. After
incubation, protein content was determined by reading the absorbance at 562 nm (Tecan Plate
Reader) with internal protein standards of bovine serum albumin (BSA).
3.1.4 Confocal internalization studies
To allow cells to adhere to glass, 8 well plates (cover glass thickness) were incubated
with fibronectin (20 µg/mL) for 30 min at 25 ◦C. MDA-MB-231 cells (2.5 x 104 cells/well)
were allowed to adhere overnight, and then cells were incubated with HA-DOX conjugates
or DOX for 4 or 24 h. After incubation, cells were immediately washed with PBS 2x, and
then the nuclei were stained for 15 min at 37 ◦C with Hoechst 33342 in live cell imaging
buffer. After staining, cells were imaged live with confocal microscopy using a temperature
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controlled stage (Olympus Fluoview 1000 Spectral Confocal). Hoechst and DOX were imaged
using excitation/emissions of 350/461 and 480/570 nm, respectively.
3.2 Determination of synergy with combination index (CI)
In order to screen through drug pairs, a metric needs to be used to quantify the degree in
which two or more drugs produce a synergistic effect without any knowledge of biological
mechanism [22]. Over ten different analysis methods have been proposed to quantify synergy
[20]. The most encompassing technique used is the calculation of a combination index (CI),
which also involves using the median effect model to describe the toxicity induced from a
single drug. The technique, developed by Chou and Talalay, is consistent with many previous
methods including the isobologram method from Frazer, the idea of Loewe additivity, Bliss
independence, and the interaction index method developed by Berenbaum [131, 132, 20, 22].
Assuming two drugs are mutually exclusive, the median effect analysis says that the dose
response to a drug combination should be a summation of the response to each of the individual
drugs:
[
( fa)1,2
( fu)1,2
]m
=
[
( fa)1
( fu)1
]m
+
[
( fa)2
( fu)2
]m
=
(D)1
(Dmed)1
+
(D)2
(Dmed)2
where m indicates the order, (D)i the dose given of drug i, and (Dmed)i the dose of drug
i required to produce a median effect [21]. Any interactions between the two drugs, whether
synergistic or antagonistic, will produce a fraction affected that is not consistent with this
analysis. The combination index is an adaptation of this equation and is used to quantify the
degree in which the two drugs interact with each other. Using the previous equation as a basis,
the combination index, for any number of drugs, is defined as:
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CI =∑
i
(D)i
(Dx)i
where i indicates each drug used in the study, Dx represents the dose required to produce the
specific fraction affected with the median effect analysis, and D represents the actual dose given
in the combination study. A CI > 1 indicates an antagonistic interaction, a CI = 1 indicates an
additive effect, and a CI < 1 indicates a synergistic effect. Typically, a CI < 0.8 is required for
two drugs to exhibit “moderate synergism” [21].
The previous analysis was developed to quantify synergy for the concurrent exposure of
multiple drugs. It has been suggested that the analysis can also be used to quantify synergy
when drugs are exposed sequentially, if a dose response curve is generated for each individual
drug that matches the exposure time and schedule used in the combination scheduling study
[21]. For example, if drug A is pulsed for 1 day and then drug B is pulsed for 1 day, the
dose response curves for each drug must be generated for a 1 day pulse of drug A and a 1 day
pulse of drug B with the 1 day initial time delay. This analysis has been used to show that
specific combinations of cancer drugs exhibit schedule dependent synergy in various studies
[43, 41, 45, 40]. However, whether or not this analysis is the optimal way to quantify schedule
dependent synergism is unclear. It is important to consider the effect that individual drug
schedules have on cellular response because this is inherently removed from the combination
index, which is calculated using the relevant individual drug schedules.
32
Experimental methods Chapter 3
3.3 Synthesis of polymer drug conjugates
3.3.1 Synthesis of amino acid GEM amide prodrugs
3, 5-O-Bis(tert-Butoxycarbonyl)gemcitabine (1)
The alcohols on GEM were protected with BOC groups similarly as reported previously
[133]. Briefly, DBDC (3.63 g) dissolved into anhydrous dioxane (33 mL) was added dropwise
to GEM-HCl (500 mg) dissolved in 1 M KOH (33 mL) over 20 min. Reaction progress was
monitored via TLC (5:4:1 DCM:acetone:ethanol). After 40 min, the reaction was extracted
3x with ethyl acetate (70 mL) and then the oil was washed 2x with saturated brine (10 mL).
Solvent was removed with rotary evaporation and the product was dissolved into dioxane (33
mL) with more DBDC (3.63 g). 1 M KOH (33 mL) was added to the flask and allowed to stir
for 30 min. The crude product was isolated by repeating the same extraction steps in addition
to drying over MgSO4. Pure (1) was then obtained with SiO2 chromatography using a 1:1
DCM:acetone mixture. Yield: 55-60 %,1H NMR (DMSO) δ 1.41 (s, 9H, BOC), 1.44 (s, 9H,
BOC), 4.30-4.41 (m, 3H, 4 and 5), 5.23 (b, 1H, 3), 5.79 (d, 1H, 5), 6.20 (b, 1H, 1), 7.44 (s, 2H,
NH2), 7.52 (d, 1H, 6).
4-glycl-gemcitabine (2)
Glycine was conjugated to the amine on GEM to form (2). Briefly, the carboxylic acid
on BOC-glycine (45.4 mg) was activated with TBTU (83.1 mg) and DIPEA (67.7 L) in an-
hydrous DMF (2 mL) for 30 min. Product (1) (100 mg), dissolved into anhydrous DMF (2
mL) with DIPEA (37.5 L) was mixed with activated BOC-glycine and reacted for at least 30
min. After removing the DMF with rotary evaporation at 65 ◦C, the product was dissolved
into ethyl acetate and washed with DI water, saturated NaNHCO3, and saturated brine. The
crude product was then dried over MgSO4 and then isolated with SiO2 chromatography (20:1
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ethyl acetate:hexanes). The BOC groups were then deprotected in a 1:1 TFA:DCM mixture
and the solvents were removed with rotary evaporation. Yield: 60-65 %, 1H NMR (DMSO) δ
3.62-3.66 (q, 1H, 5), 3.76-3.83 (m, 1H, 5), 3.86-3.92 (m, 3H, 4 + glycine side), 4.17 (m, 1H,
3), 6.16 (m, 1H, 1), 7.10 (d, 1H, 5), 8.15 (b, 3H, NH3), 8.30 (d, 1H, 6), 11.42 (b, 1H, NH).
4-L-valyl-gemcitabine (3)
Valine was conjugated to GEM to form (3) identically to how (2) was synthesized. Yield:
50-55 %, 1H NMR (DMSO) δ 0.91-0.97 (dd, 6H, valine methyl), 1.96 (s, 1H, valine), 3.62-64
(q, 1H, 5), 3.77-3.82 (m, 1H, 5), 3.85-3.91 (m, 2H, 4 + valine side), 4.16 (m, 1H, 3), 6.16 (m,
1H, 1), 7.22 (d, 1H, 5), 8.33 (d, 1H, 6), 11.4 (b, 1H, NH).
3.3.2 Synthesis of HA polymer drug conjugates
DOX-HA amide, GEM-gly-HA, and GEM-val-HA were all synthesized using a similar
procedure. Briefly, sodium hyaluronate (50 kDa, 7.5 mg/mL) was dissolved in 1:1 deionized
water:DMSO. Sulfo-NHS (20-40 mol % relative to dissacharide repeat unit) was dissolved
into DI Water and EDC-HCl (20-40 mol %) was dissolved into DMSO, and both solutions
were added to the HA solution. DOX-HCl (10-40 mol %) or the GEM prodrug (10-40 mol
%) was dissolved into DMSO and added to the reaction. The reaction proceeded overnight at
room temperature, and the polymer drug conjugate was purified through repeated precipitation
and washing steps in ethanol/PBS mixtures.
DOX-HA hydrazone was synthesized similar to previous reports [134, 135]. Briefly, HA
(50 kDa, 10 mg/mL) and adipic acid dihydrazide (300 mol % relative to dissacharide repeat
unit) were dissolved into DI water. The pH was then adjusted to 4.75 with 1 M HCl, and then
EDC-HCl (20 mol %) was added to the solution. After reacting for 5 h, the polymer (HA-
ADH) was precipitated and washed 2x in ethanol/PBS. HA-ADH was then dissolved into 1:1
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DI water:DMSO (1.25 mg/mL) and DOX-HCl (10-20 mol %) was dissolved into DI water (2.5
mg/mL) and added quickly to HA-ADH while stirring vigorously. After reacting for 3 to 5
h, DOX-HA hydrazone was then isolated through repeated precipitation and washing steps in
ethanol/PBS.
3.4 Characterization of delivery vehicles
3.4.1 Drug release kinetics
Release kinetics of drugs from delivery vehicles was determined through dialysis. Vehicles
were dissolved into either PBS at pH 7.4 or pH 5 (adjusted with 1 M HCl). The vehicles
were incubated in dialysis filters (Slide-A-Lyzer MINI Dialysis Device, 10K MWCO), with
the same buffer below the filter. The bottom centrifuge was replaced with fresh buffer at each
time point. Concentrations of drug in the tubes were determined by measuring the absorbance
or drug with a TECAN plate reader.
3.4.2 Dynamic light scattering
HA conjugates were dissolved into PBS at concentrations ranging from 0.01 mg/mL to
0.10 mg/mL. The size of particles were determine using DLS on a Malvern ZetaSizer Nano
ZS. Prior to analysis, conjugate samples were centrifuged at 500 rpm for 1-2 min. to remove
large dust particles in the sample.
3.4.3 Transmission electron microscopy (TEM)
For Cryo TEM, conjugates were dissolved into PBS at a concentration of 1 mg/mL. Sam-
ples were then prepared for imaging using a Vitrobot Mark IV at room temperature and 100
% relative humidity. Prior to sample deposition, Lacey carbon coated copper grids (200 mesh)
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were plasma-treated for 20 s. After the surface treatment, samples were deposited (1.2 µL)
onto the grids and blotted once (time: 1 s, force: 2), and then immediately plunged into vit-
rifying liquid. The samples were then transferred to the cryo-TEM holder and viewed under
the FEI Tecnai G2 Sphera TEM at 200 kV. Gatan Digital Micrograph was used to record the
images acquired by the digital camera.
3.4.4 Nuclear magnetic resonance (NMR)
Synthesis steps were verified with 1H NMR (Varian VNMRS, 600 MHz). Spectrums for
small molecule drugs and prodrugs were measured in (CD3)2SO with a relaxation period of 1
s and spectrums for HA conjugate were measured in D2O with a relaxation period of 3 s.
3.4.5 UV-spectroscopy (UV-vis)
Drug loading of HA conjugates was measured with UV-vis spectroscopy (Tecan M220
Plate Reader). Conjugates were dissolved in PBS (∼ 1 mg/mL) and the concentration of drug
was determined using drug calibrations. The following molar absorption coefficients were used
(for 100 µL of liquid) for Gem-amino acid prodrugs, GEM, and DOX, respectively: ε250 =
3500 M−1, ε270 = 2800 M−1, and ε480 = 2670 M−1.
3.5 In vivo efficacy studies
All experiments were performed according to approved protocols by the Institutional Ani-
mal Care and Use Committee of the University of California, Santa Barbara.
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3.5.1 MDA-MB-231 orthotopic tumor model
A MDA-MB-231 orthotopic mouse breast cancer model was used to evaluate the efficacy
of DOX and GEM combination therapy in athymic, nude mice (Charles Rivers Laboratories).
MDA-MB-231 cells (2.5 x 106 , 100 µL of 1:1 PBS:Matrigel) were injected subcutaneously
into the inguinal mammary fat pad of 6-8 week old athymic, nude mice. Starting 11 d after
tumor transplantation, when tumors reached 50 mm3, mice were treated either once, or 4x on
a weekly basis. Tumor growth inhibition was measured with a caliper using the following
equation: V = (L ∗W 2)/2, where is the L is the longest dimension of the tumor and W is the
shortest.
3.5.2 4T1 orthotopic tumor model
A 4T1 orthotopic mouse breast cancer model was used to evaluate the efficacy of the con-
jugates in vivo in BALB/c mice (Charles Rivers Laboratories). 4T1 cells (1 x 105 , 100 µL)
were injected subcutaneously into the inguinal mammary fat pad of 6-8 week old BALB/c
mice. Starting 4 days after tumor transplantation, mice were treated every 3rd or 5th day for
a total of 4 injections. All drug formulations were prepared in sterile saline (0.9 wt/vol %
NaCl) and injected intravenously through the tail vein or subcutaneously in a mammary fat
pad. Tumor growth inhibition was again measured with a caliper using the following equation:
V = (L∗W 2)/2, where is the L is the longest dimension of the tumor and W is the shortest. Due
to the aggressive growth of 4T1 tumors, some mice had to be euthanized prior to significant
weight loss (> 15% body weight) or large tumor sizes (> 1500 mm3) due to necrotic, tumor
ulcers.
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Identifying schedule-dependent synergy in
breast cancer
Breast cancer is the second most common type of cancer in females, representing 29% of fe-
male cancer cases and 14% of all female cancer related deaths [136]. Breast cancer mortality
rates have decreased by 34% from 1990 to 2010 [137]; however, this is more commonly at-
tributed to increase in early prognosis as opposed to vast improvements in treatment [138].
With an annual death rate of approximately 40,000 [136], breast cancer remains an active area
of research.
In the clinic, the primary treatment for most breast cancer cases is the surgical removal
of cancerous mass, which can entail breast-conserving surgeries such as a lumpectomy or a
quadrentectomy or complete removal of the entire breast with a mastectomy. Depending on
the size and location of the initial tumor, chemotherapy, hormonal, and/or targeted therapy will
often be given post surgery, called adjuvant therapy, to kill any remaining cancer cells in order
to prevent relapse. In addition, chemotherapy is often given prior to surgery, called neoadjuvant
therapy, to help reduce the size of the tumor and allow for a smaller surgical operation. For
severe cases which are initially inoperable due to their size, this step is necessary for surgical
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operation [138]. For advanced cases of breast cancer, prognosis is often poor due to tumor
cells not responding to treatment regimens. The lack of response is typically attributed to
innate and/or adaptive drug resistant processes [138].
This chapter focuses on the in vitro identification of synergistic chemotherapy drug pairs
for treating breast cancer cells. The main objective is to identify synergistic drug pairs which
can be incorporated into a single delivery vehicle to treat a specific phenotype of breast can-
cer. A panel of FDA approved chemotherapy drugs are screened against two different breast
cancer cell lines, with a focus on understanding how drug administration schedule impacts
the ability for a drug pair to inhibit tumor growth. After identifying a drug pair which demon-
strates schedule-dependent synergy, the drug pair is evaluated in vivo to see the in vitro synergy
improves efficacy in vivo.
4.1 Cell lines and drug panel to probe for synergy
Treatment options for breast cancer depend upon the phenotype of the tumor mass, which
is generally based on the expression levels of the estrogen receptor (ER), human epidermal
growth factor receptor 2 (HER2), and progesterone receptor (PR). The different phenotypes of
breast cancer are generally grouped into the following categories: Luminal A (ER+, HER2−,PR±),
Luminal B (ER+, HER2+,PR±), Basal (ER−, HER2−,PR−), Claudin-low (ER−, HER2−,PR−),
and HER2 type (ER−, HER2+,PR−) [139, 140, 141]. Generally speaking, tumors which do not
over-express ER, HER2, or PR, are also referred to as triple negative [142]. While chemother-
apy is often used to treat all late stage breast cancer patients regardless of phenotype, a high
fraction of Luminal B and triple negative tumors are treated with chemotherapy.
Luminal B tumors are extremely aggressive and often metastasize elsewhere in the body,
and therefore require systemic chemotherapy in combination with targeted therapies to help
prevent and slow down disease progression. Similarly, triple negative tumors do not over-
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express any of the common receptors and are therefore unresponsive to many of the targeted
therapies, and, thus, have to be treated systemically with chemotherapy. In this report, the BT-
474 and MDA-MB-231 cells lines are used as representive cell lines for Luminal B and triple
negative type breast cancers, respectively. The BT-474 cell line, which was isolated from a
solid, invasive ductal breast carcinoma [143], has been established as a representative cell line
for Luminal B tumors [140]. MDA-MB-231 is a metastatic cell line which was obtained with
a pleural effusion from a patient with an intraductal carcinoma [144], and is commonly used
as a model cell line for triple negative breast cancer [142].
With over 60 FDA approved drugs for breast cancer, clinicians have a large repertoire of
small molecule therapeutics and targeting agents to utilize for treatment. Many of the drugs
share similar structure and mechanisms, and most of the commonly used chemotherapeutic
agents can be placed in the following functional categories:
1. Alkylating agents: Induce DNA damage
2. Antimetabolites: Interfere with metabolism of molecules
3. Anthracyline antibiotics: Interfere with DNA replication
4. Estrogen receptor antagonists: Interfere with cell cycle progression
5. Taxanes and epothilones: Inhibit mitosis
Based on the stage and phenotype of the breast cancer, various treatments are used contain-
ing one or a combination of these drugs. For preliminary studies examining the effect of drug
scheduling on single agent efficacy and combination therapy, five representative drugs were
used (Figure 4.1). Each drug is a commonly prescribed agent from its respective category,
where doxorubicin (DOX) is an anthracyline antibiotic, paclitaxel (PTX) a taxane, ixabepilone
(IXA) an epothilone, gemcitabine (GEM) an antimetabolite, and lapatinib (LAP) an estrogen
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receptor antagonist. A brief overview of the clinical application of each drug is now presented
along with the relevent cellular mechanisms of drug induced toxicity.
Doxorubicin·HCl Paclitaxel Ixabepilone
Gemcitabine·HCl Lapatinib, Di-p-Toluenesulfonate
Figure 4.1: Small molecule therapeutics used for cell-drug studies
Doxorubicin (Adriamycin R©) is a commonly used anthracyline antibiotic in breast cancer
for adjuvant and neoadjuvant therapy. It is used both individually and in various combina-
tion therapies, including TAC (docetaxel, doxorubicin, and cyclophosphamide) [145, 146], AC
→ T (doxorubicin and cyclophosphamide followed by paclitaxel) [147, 148], and FAC (5-
Fluorouracil, doxorubicin, and cyclophosphamide) [149]. Many mechanisms of drug induced
toxicity have been observed in vitro including intercalation of drug into DNA, generation of
free radicals, and inhibition of topoisomerase II, with the inhibition of topoisomerase II ap-
pearing to be the most plausible mechanism under in vivo conditions [150, 151].
Paclitaxel (Taxol R©), one of the commonly prescribed taxanes, is used in various chemother-
apy regimens. It is used in one of the commonly prescribed combination regimens (AC→ T
[147, 148]), and is also used to treat late stage, metastatic HER2+ cancer in combination with
trastuzumab [152, 153]. Paclitaxel elicits cell death by binding along the length of microtubules
and increasing stability, which both promotes microtubule polymerization and decreases de-
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polymerization dynamics [154]. Apoptosis is then triggered by either preventing mitosis and
triggering cell cycle arrest during the G2-M phase at high drug concentrations or through other,
unclear mechanisms at lower drug concentrations [155].
Ixabepilone, an epothilone analog, was recently approved for the treatment of metastatic
breast cancer. In particular, ixabepilone has shown potential in treating metastatic breast can-
cer patients which have become resistant to taxane therapy [156]. It has also shown activity
in taxane resistant breast cancer patients when combined with capecitabine or trastuzumab
[157, 158, 159]. Similar to taxanes, ixabepilone binds to microtubules, promoting growth and
preventing mitosis. Interestingly, cells which overexpress P-gp and are resistant to paclitaxel,
are still sensitive to ixabepilone [156].
Lapatinib (Tykerb R©) is a small molecule antagonist of epidermal growth factor receptor
(EGFR) and HER2. It has successfully been used in the clinic in combination with Capecitabine
[160], an anti metabolite, for late stage HER2+ cancer. It also has shown promise as a potential
solution to cells which have become resistant to trastuzumab, a more commonly used HER2 an-
tagonist [161]. As opposed to trastuzumab, which binds to the extracellular portion of HER2,
lapatinib binds to the intracellular ATP-binding domain of the receptor tyrosine kinase. All
downstream activities of HER2 become blocked, which reduces cell growth and proliferation.
Gemcitabine (Gemzar R©) is a pyrmidine antimetabolite which is the gold standard for treat-
ing pancreatic cancer. Gemcitabine has also shown promise in treating late stage breast cancer
[162], and combinations with trastuzumab or paclitaxel have reported good response in pa-
tients already treated with chemotherapy in Phase II/III clinical trials [163, 164]. Gemcitabine
inhibits tumor growth by being incorporated into DNA chains and inhibiting DNA synthesis
[165].
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4.2 Single drug toxicity screening
To identify synergistic drug pairs, the dose response of single drugs was first measured.
BT-474 and MDA-MB-231 cells were exposed to each therapeutic agent for 72 h (Fig. 4.2).
Cell viability was measured with the MTT assay at the end of drug exposure. To estimate the
IC50 of each drug, cell viability was fit to the median effect model [21].
Figure 4.2: Growth inhibition of (a) BT-474 cells and (b) MDA-MB-231 cells after 72 h
of single drug exposure. Markers represent experimental data and curves represent best fit
median effect model. Error bars represent 95 % CI (n ≥ 12 wells).
Table 4.1: IC50 values
Drug BT-474 IC50 (µM) MDA-MB-231 IC50 (µM)
DOX 1.3 ± 0.2 0.28 ± 0.02
GEM – > 50
IXA 0.037 ± 0.002 0.019 ± 0.005
LAP 0.09 ± 0.01 –
PTX 0.014 ± 0.001 0.015 ± 0.003
After 72 h of drug exposure, BT-474 and MDA-MB 231 cells are both responsive to DOX,
PTX, and IXA, with similar magnitude IC50 concentrations (Table 4.1). On the contrary, BT-
474 cells are not responsive to GEM and MDA-MB-231 cells are not responsive to LAP. Con-
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sidering that MDA-MB-231 cells are triple negative and do not over express HER2, it is not
surprising that LAP does not have any toxic effect on the cell line.
4.3 Screening of drug synergy in BT-474 cells
After establishing the relative toxicity of each drug individually, drugs were tested in com-
bination in attempt to identify synergistic drug pairs. First cells were exposed concurrently to a
combination of drugs at single drug doses between the respective IC25 and IC50 concentrations.
This concentration range was used to ensure that the drug dose was high enough to impact cell
viability without killing all of the cancer cells. The drug pairs of DOX/LAP, IXA/LAP, and
IXA/PTX are found to be synergistic, as the drug combinations inhibit BT-474 cell growth
more than the individual drugs, resulting in CI values less than 1 (Fig. 4.3). It is possible the
other drug pairs are also synergistic at different drug ratios; however, this was not explored
further in this study.
Figure 4.3: Synergy (expressed as CI) of combinations of LAP (0.025 µM), PTX (0.01 µM),
IXA (0.03 µM), and DOX (0.6 µM) after 72 h, concurrent drug exposure on BT-474 cells.
Error bars represent 95 % CI (n ≥ 12 wells)
BT-474 cells were then sequentially exposed to the same drug pairs, to determine if drug
administration schedule impacts cellular proliferation (Fig. 4.4). For example, Drug A was
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Figure 4.4: Fractional cell inhibition of BT-474 cells after the sequential exposure of (a) DOX
(0.6 µM) and LAP (0.025 µM), (b) DOX (0.6 µM) and PTX (0.01 µM), (c) LAP (0.025 µM)
and IXA (0.03 µM), and (d) PTX (0.01 µM) and IXA (0.03 µM). The first drug was aspirated
and replaced with the second drug at the specified time points and cell viability was measured
at 72 h. Error bars represent 95 % CI (n ≥ 12 wells).
given to the cells for 4, 12, 24, or 36 h and then replaced with Drug B for the remaining time in
the 72 h drug exposure. Drug synergy (or CI) cannot be determined directly from these results
because dose response curves were not found for each individual drug at the schedule given
in the combination treatment. The effect of schedule on drug synergy will be determined for
specific drug pairs in upcoming sections.
The schedule in which BT-474 cells are exposed to PTX and IXA has no impact on cellular
viability; however, cell viability is significantly impacted by drug exposure schedule for all of
the other drug pairs. The combinations of LAP/IXA and LAP/DOX, which are both synergistic
when given concurrently, are most effective at inhibiting cell growth when LAP is given for 4
h prior to IXA or DOX or if LAP is given 24-36 h after IXA or DOX exposure. The combina-
45
Identifying schedule-dependent synergy in breast cancer Chapter 4
tion of PTX and DOX, which is antagonistic when given concurrently, is more toxic with the
following schedules than when given concurrently: PTX (4 h)→ DOX (68 h) and DOX (36 h)
→ PTX 36 h.
It is clear that the schedule in which most chemotherapy drug pairs are exposed to BT-
474 cells significantly impacts cellular toxicity. Because the combinations of LAP/DOX and
LAP/IXA are synergistic when given concurrently and induce a different cellular response
based on schedule, the effect of drug schedule on synergy should be explored further in future
studies. Synergy may be enhanced if the drugs are sequenced more effectively. Based on these
results, the effect of schedule on synergy is examined in detail for LAP and PTX, which has
a similar mechanism of toxicity as IXA, in Chapter 6. LAP and PTX are incorporated into
polymeric nanoparticles to take advantage of these synergistic interactions.
4.4 Screening of drug synergy in MDA-MB-231 cells
Figure 4.5: Synergy (expressed as CI) of combinations of GEM (0.2 µM), PTX (0.005 µM),
IXA (0.015 µM), and DOX (0.3 µM) after 72 h, concurrent drug exposure on MDA-MB-231
cells. Error bars represent 95 % CI (n ≥ 12 wells)
MDA-MB-231 cells were also exposed to combinations of therapeutic agents for 72 h at
single drug dose between the IC25 and IC50 concentrations (Fig. 4.5). Only the combinations
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of GEM/DOX and IXA/PTX were synergistic at inhibiting tumor cell growth. Interestingly, the
combination of IXA and PTX, which have similar mechanisms of toxicity, were also synergistic
at inhibiting growth of BT-474 cells.
Figure 4.6: Fractional cell inhibition of MDA-MB-231 cells after the sequential exposure of
(a) DOX (0.3 µM) and PTX (0.005 µM), (b) DOX (0.3 µM) and GEM (0.2 µM), (c) DOX
(0.3 µM) and IXA (0.015 µM), (d) PTX (0.005 µM) and IXA (0.015 µM), and (e) PTX
(0.005 µM) and GEM (0.2 µM). The first drug was aspirated and replaced with the second
drug at the specified time points and cell viability was measured at 72 h. Error bars represent
95 % CI (n ≥ 12 wells).
Consistent with experiments done with BT-474 cells, MDA-MB-231 cells were then ex-
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posed sequentially to each drug combination (Fig. 4.6). The combination of GEM and DOX,
which is synergistic with a CI of 0.53 ± 0.05 when given concurrently, is significantly more
toxic when cells are exposed to GEM prior to DOX. Furthermore the combinations of DOX
with the two mitotic inhibitors (PTX and IXA) are more toxic when PTX or IXA is given prior
to DOX. Consistent with BT-474 cells, the toxicity of PTX and IXA showed minimal schedule
dependence on MDA-MB-231 cells. Due to the significant difference in cellular toxicity after
exposure to different DOX and GEM schedules, the synergy of this drug pair is explored in the
upcoming section.
4.5 DOX and GEM synergy in vitro
To examine the schedule dependence of synergy between DOX and GEM in more detail,
dose response curves of each drug at different schedules were measured on MDA-MB-231
cells (Fig .4.7). The toxicity of each drug decreases as the cells are exposed to the drugs for a
shorter time period. In addition, the time point of the initial drug exposure relative to the end
point assay influences final cell viability.
Cells were exposed to different schedules of GEM and DOX over 72 h and viability was
measured after treatment (Fig. 4.8). The dose selected to determine schedule-dependent syn-
ergy (0.3 µM) is approximately the IC50 of DOX and less than the IC50 of GEM. Simultaneous
treatment with both drugs and incubation with GEM prior to DOX induced more toxicity than
treatment with DOX prior to GEM. Incubating the cells with GEM 1 day prior to DOX (CI
= 0.16 ± 0.03) is more synergistic compared to the pair’s simultaneous treatment (CI = 0.76
± 0.10). Furthermore, it is more synergistic if the cells are exposed to GEM prior to DOX
compared to DOX prior to GEM, regardless if the first drug is removed (Fig. 4.8 a-c) or not
(Fig. 4.8 d-f).
In addition to human, triple negative breast cancer cells (MDA-MB 231), the effect of
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Figure 4.7: Fractional cell inhibition and relevant dose response curves for MDA-MB-231
cells after exposure to (a) DOX→ media (b) media→ DOX (c) GEM→ media (d) media→
GEM. Cell viability was assessed at 72 h for each schedule. Error bars represent 95 % CI (n
≥ 18 wells).
schedule on synergy was determined for non-cancerous, immortalized human breast epithelial
cells (MCF-10a) and murine, triple negative breast cancer cells (4T1). The schedule of GEM
(1 d)→ DOX (2 d) is the most synergistic schedule for the MDA-MB-231 and 4T1 cells, while
the schedule is the least synergistic for the MCF-10a cells (Fig. 4.9a). Scheduling GEM to
DOX is extremely synergistic on the cancer cells (CI < 0.2) across all dose ratios, while it is
antagonistic on the non-cancerous cells for GEM:DOX ratios greater than 1 (Fig. 4.9b).
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Figure 4.8: Effect of GEM and DOX schedule on synergy. (a) and (d) Schedules of DOX
(0.3 µM) and GEM (0.3 µM) incubation on MDA-MB-231 cells. (b) and (e) Cell inhibition
of GEM, DOX, and combinations at schedules specified in (a) and (d), respectively. Cell
viability measured with the MTT assay. (c) and (f) Combination index of schedules of DOX
and GEM calculated with the Chou-Talalay method. Data represent mean ± 95 % C.I. (n ≥
12 wells).
4.6 Mechanistic studies of DOX and GEM
To further explore the effect of schedule with DOX and GEM on tumor growth inhibition,
apoptosis activity was measured. Specifically, the amount of activated Caspase-3, which is the
last executor caspase enzyme for both extrinsic and intrinsic apoptotic pathways, was measured
after exposure to different drug schedules. Following 3 d of drug exposure, cells treated with
GEM prior to DOX show more caspase activity than cells treated both with the drug pair
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Figure 4.9: Effect of administration schedule on synergy for MCF-10a, MDA-MB-231, and
4T1 cells. GEM and DOX were given at an equimolar ratio near the IC50 dose at concen-
trations of 0.01 µM for MCF-10a and 4T1 cells and 0.30 µM for MDA-MB-231 cells. (b)
Synergy for schedule of GEM (1d) → DOX (2d) with varying molar ratio of GEM:DOX.
Data represent mean ± 95 % confidence intervals (n ≥ 6 wells).
simultaneously and with DOX prior to GEM (Fig. 4.10).
Figure 4.10: Effect of GEM and DOX schedule on initiation of apoptotic pathways measured
with Caspase 3 activity normalized to total protein content. Data represents mean ± SEM
(n=3).
GEM and DOX are known to be highly active in specific stages of the cell cycle. There-
fore, to gain mechanistic insight on why GEM→ DOX is more effective at inhibiting cancer
cell growth than other schedules, cell cycle distribution after drug exposure was measured by
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incubating cells with the nuclear stain P.I. (Fig. 4.11). Exposing MDA-MB-231 cells to GEM
or DOX induces cell cycle arrest in the G0/G1 phases or G2/M phases, respectively. After ex-
posure to GEM, the accumulation of cells into the G0/G1 phase is dose-dependent, with more
cells accumulating in the S phase at lower GEM doses (Fig. 4.11c). Furthermore, after 1 d
exposure to a high GEM dose (0.30 µM), cells remain locked in a similar cell cycle state for at
least 2 d after drug exposure.
Figure 4.11: Cell cycle distribution of MDA-MB-231 cells after exposure to GEM, DOX,
and GEM/DOX combinations measured with P.I. nuclear staining. (a) + (b) 72 h drug expo-
sure (0.30 µM) (c) 72 h drug exposure at noted concentrations (d) 24 h of GEM (0.30 µM)
exposure and a media washout
After incubation with GEM, MDA-MB-231 cells reach a similar cell cycle distribution
after only 1 d of drug exposure. On the contrary, the cell cycle distribution continues to change
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days after DOX exposure (Fig. 4.12). Exposing the cells simultaneously to GEM and DOX or
exposing cells to GEM prior to DOX induces arrest in the G0/G1 phases, similar to exposing
cells just to GEM. However, exposing cells to DOX prior to GEM induces arrest in the G2 and
S phases.
Figure 4.12: (a) Evolution of cell cycle distribution of MDA-MB 231 cells after exposure
to DOX (0.3 µM) or GEM (0.3 µM) measured with flow cytometry using PI. (b) Cell cycle
distribution of MDA-MB-231 cells after exposure to various schedules of DOX and GEM in
combination (0.3 µM).
4.7 In vivo tumor studies with DOX and GEM
To determine if the in vitro synergy between free DOX and GEM translates to improved
efficacy in vivo, a MDA-MB 231 orthotopic tumor model was used. In the first study, mice
received one cycle of chemotherapy consisting of either DOX, GEM, DOX→ GEM, or GEM
→ DOX. Using low doses of both DOX (2 mg/kg) and GEM (20 mg/kg), the schedule of GEM
→ DOX stopped tumor growth up to 20 d post treatment, which is significantly more effective
than DOX or GEM on its own (Fig. 4.13a-b). The schedule of GEM → DOX (which was
determined to be most effective in vitro) is only marginally more effective than the reverse
schedule of DOX→ GEM.
Next, 4 weekly injections of chemotherapy were given to attempt to eradicate the tumors.
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Figure 4.13: Tumor growth studies on MDA-MB-231 orthotopic xenografts in athymic, nude
mice. All DOX (2 mg/kg) and GEM (20 mg/kg) doses are consistent for both studies and all
experimental groups. The GEM→ DOX and DOX→ GEM groups have a 1 d delay between
the injection of each drug. (a) Tumor growth inhibition with one i/v injection starting on day
11. (b) Final tumor volume for the study in (a). (c) Tumor growth inhibition with 4 x 1w i/v
injections starting on day 11. (d) Average body masses throughout the course of injections
shown in (c).
Again, the combinations of GEM→ DOX and DOX→ GEM are significantly more effective
in inhibiting tumor growth than the individual drugs (Fig. 4.13c). Both schedules of DOX
and GEM were able to stop tumor growth up to approximately 45 d; however, all the tumors
eventually relapsed. It is important to note that the repeated injections of the low doses of GEM
and DOX caused no observable toxicity as evident by no change in body weight throughout
the course of the study (Fig. 4.13d).
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4.8 Discussion of GEM and DOX synergy
Prior to engineering a combination vehicle with DOX and GEM, we wanted to fundamen-
tally understand how the drugs interact while inhibiting tumor growth. The effect of drug
administration schedule and drug ratio on synergy was studied to minimize drug dose required
to inhibit cancer cell growth. Similar to previous reports, DOX and GEM are synergistic while
inhibiting the growth of various cancer cell lines [166]. Interestingly, in both human (MDA-
MB 231) and murine (4T1) triple negative breast cancer cells, the schedule in which the cells
are exposed to the drugs has a larger impact on drug synergy than drug ratio. For both cell
lines, it is more synergistic to expose the cells to GEM prior to DOX; furthermore, the CI is
as low as 0.2 while giving GEM for 1d followed by DOX on MDA-MB-231 cells indicating
that a 5x fold lower dose can be used. Interestingly, the schedule of GEM (1d)→ DOX (2d)
is not synergistic on immortalized, healthy breast epithelial cells (MCF-10a) if GEM is given
in molar excess of DOX. This provides evidence that by manipulating the schedule and ratio
in which you expose cells to DOX and GEM, it is possible to selectively induce more toxicity
towards cancer cells (MDA-MB 231 and 4T1) compared to healthy cells (MCF-10a).
The increase in synergy upon giving GEM prior to DOX is consistent with an increase in
caspase dependent apoptosis (Fig. 4.10). Exposing MDA-MB 231 cells to GEM (1d)→ DOX
(2d) compared to the simultaneous treatment with GEM and DOX for 3d leads to two times
more caspase activity, even though the cells are exposed to each drug for less time. Previous
reports have also shown that the schedule in which cancer cells are exposed to chemotherapeu-
tic drugs can significantly impact the induction of pro-apoptotic pathways [32]. In addition,
another study has shown that the pre-exposure of GEM increases the toxicity of topoisomerase
inhibitors, such as DOX [167].
The strong dependence of tumor cell death on GEM and DOX administration schedule is
likely related to the cell-cycle phase dependent mechanisms of both drugs. After exposure
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to GEM, MDA-MB 231 cells accumulate in the G0/G1 and S phases of the cell cycle, while
they accumulate in the G2 phase after exposure to DOX (Fig. 4.11 and 4.12), consistent with
previous reports [168, 169, 165]. After exposure to combinations of both DOX and GEM, their
cell cycle distribution closely matches that of the drug which the cells were exposed initially to.
When exposing the cells to GEM and DOX simultaneously, the resulting cell cycle distribution
is more similar to GEM, most likely due to the faster kinetics of cell cycle arrest after GEM
exposure.
Both the toxicities of DOX and GEM have shown to be enhanced while treating cells in
the early S phase of the cell cycle [170, 171]. Because DOX induces cell cycle arrest in the
G2 phase, it is not surprising that giving GEM after DOX is the least toxic administration
schedule. On the contrary, because GEM arrests cells in the G0/G1 and early S phases, the cells
are sensitized to subsequent DOX treatment. From in vitro toxicity, it is difficult to identify an
optimal pre-exposure time of GEM prior to DOX. Given that the cell cycle distribution remains
the same after 1 d exposure of GEM this is not surprising (Fig. 4.12). In addition, because the
cells remain in a locked cellular state for days after removing GEM, a longer delay between
GEM and DOX exposure also seems satisfactory to induce the synergistic effect.
It is evident that combining GEM and DOX is effective at inhibiting MDA-MB-231 cell
growth in vitro, and this was verified in vivo. In combination, low doses of DOX and GEM
(2 mg/kg and 20 mg/kg, respectively) are effective at inhibiting tumor growth up to 50 d in an
orthotopic, MDA-MB-231 tumor xenograft. In combination, the cumulative dose of both DOX
and GEM is significantly lower than the single drug doses required to inhibit tumor growth in
other human xenograft tumor studies [172, 173, 174, 175]. Surprisingly, the schedule of GEM
→DOX is only marginally more effective at inhibiting tumor growth than the schedule of DOX
→ GEM (Fig. 4.13). While the schedule of DOX→ GEM was still found to be synergistic in
vitro, it is surprising that it was as effective in vivo as the reverse schedule even with a much
higher combination index. Further research is required to understand why the optimal schedule
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of GEM and DOX in vitro did not translate to in vivo. A possible explanation is the difference
in cell behavior in vivo compared to in vitro.
4.9 Conclusions on drug synergy screening
By looking at cell viability after exposing MDA-MB-231 and BT-474 cells to different
schedules of chemotherapy drugs in vitro, it is clear that drug schedule plays a critical role
in the effectiveness of a drug pair compared to the single drugs. Sequentially exposing cells
to one drug prior to another, can induce a cellular response which makes the cell much more
susceptible to the toxic effects of the second drug. The drug pairs and schedules which were
identified as synergistic here will not be synergistic for all patient tumors, stressing the im-
portance of personalizing drug combinations for each individual patient. However, it is clear
that both drug ratio and schedule can significantly impact how effective a given drug pair is at
inhibiting tumor growth.
While in vitro studies provide a starting point for identifying effective drug combinations,
many of the specific drug interactions may not be applicable to the in vivo environment. The
drug combination of GEM and DOX was synergistic at inhibiting the growth of MDA-MB-
231 cells in vitro. Furthermore, optimization of the drug pair showed that giving GEM prior
to DOX enhanced this synergy in vitro. While the drug pair was significantly more effective
at inhibiting MDA-MB-231 cell growth in vivo than the single drugs, the sequential adminis-
tration schedules of giving GEM prior to DOX or DOX prior to GEM were equally effective
in vivo. The optimization on drug schedule carried out with in vitro studies did not translate to
the in vivo tumor model, motivating future drug combination optimization to be carried out in
more realistic in vitro models and in in vivo studies.
Lastly, each chemotherapeutic agent distributes and circulates uniquely in the body, making
it difficult to predict the exposure of each drug. This will not only impact the effectiveness of
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the drug pair at inhibiting the growth of tumor cells, but also how the drug pair interacts with
healthy tissue in the body. By incorporating a drug pair into a single delivery vehicle, drug
ratio and release can be controlled throughout the body, taking advantage of optimal drug
interactions.
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Engineering polymer drug conjugates to
deliver GEM and DOX
GEM, an antimetabolite, and DOX, a topoisomerase II inhibitor, have been tested in various
combinations in the clinic due to different mechanisms of dose limiting toxicity (neutropenia
and cardiac toxicity, respectively) [176, 177, 178, 179, 180]. Similarly, the liposomal formula-
tion of DOX (DOXIL) and GEM have been tested in combination [181]. However, in each of
the clinical trials, moderate efficacy was reported over the individual agents, with more severe
side effects reported in the majority of the trials, most notably neutropenia.
In attempt to improve the efficacy of combination treatment with GEM and DOX, various
delivery vehicles have been designed to deliver DOX and GEM together, including HPMA
polymer drug conjugates, silica nanoparticles, polymersomes, micellar nanoparticles, and hy-
drogel nanoparticles [116, 182, 183, 184, 166, 185]. The vehicles have been effective at treating
various pancreatic, prostate, breast, and ovarian cancer lines in vitro, and the HPMA conjugate
has shown efficacy in vivo in an AT1 prostate cancer model [116]. Although each of these
studies demonstrate benefits by combining the drugs in a single carrier, further optimization of
the interactions between DOX and GEM can enhance the efficacy of a combination delivery
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vehicle carrying the two agents.
Here, we report on the development of a delivery vehicle to optimize the synergy between
DOX and GEM. As discussed in Chapter 4, GEM and DOX synergy is schedule-dependent;
therefore, polymer drug conjugates with hyaluronic acid (HA) are synthesized with different
DOX and GEM release rates. The activity of the conjugates are evaluated on cancer cells in
vitro and in an aggresive, orthotopic tumor model in vivo.
5.1 Hyaluronic Acid (HA) carriers
Hyaluronic acid (HA), a naturally occurring polysaccharide found in the extracellular ma-
trix of various tissues, is a commonly used polymer in drug delivery [80, 186]. In the body,
HA varies in molecular weight from a few kDa to 20 MDa and is directly involved in many
biological processes including inflammation, wound repair, and morphogenesis. Due to the
natural abundance of enzymes (hyaluronidases) which degrade HA, the polymer has an ex-
tremely short half life in the body making it biocompatible. In addition, HA is known to play a
significant role in many cancers, as the natural receptor for HA (CD44) is often over-expressed
by tumor cells.
Because HA is biocompatible, hydrophilic, and generally non-immunogenic, HA is com-
monly used in delivery systems for treating different cancers. Multiple studies have shown
that coating a nanoparticle or liposome surface with HA can improve targeting of therapeutics
to CD44 over-expressing tumors and increase drug circulation time [187, 188, 189, 190]. In
addition, drugs can be conjugated directly to HA, forming HA-conjugates, to improve drug
solubility and bioavailability [135, 191, 192, 134, 193]. Often times, HA-conjugates will self
assemble into nanoparticles or micelles depending on the hydrophobicity of the conjugated
drug.
There are multiple synthetic routes which drugs can be conjugated to HA, summarized in
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a previous review [194]. Typically, drugs or pro-drugs are conjugated to the carboxylic acid
or an alcohol on HA; however, other synthetic routes have also been utililized by manipulat-
ing another functional group on HA. In particular, many chemotherapeutic agents have been
conjugated to the carboxylic acid of HA. PTX and GEM were conjugated with ester bonds
[192, 195], GEM with an amide bond [193], and PTX with an ester bond using amino acids
as chemical linkers [192]. DOX has been conjugated directly with an amide bond and with a
hydrazone bond using adipic acid dihydrazide as a chemical linker [135, 134]. In addition, CIS
has been been conjugated via Pt coordination with the carboxylic acid [191].
HA has been used to deliver chemotherapeutic agents through various administration routes.
Due to the short half of HA in the plasma, many preliminary studies focused on localized ther-
apy with HA-drug conjugates. HA-CIS and HA-DOX were effective at treating breast can-
cer xenografts with localized, subcutaneous injections [191, 134, 113]. After injection of the
conjugates, no local inflammation was observed. In addition, HA-PTX, administered intraves-
ically, was effective at treating bladder cancer that is resistant to the gold standard treatment
(bacillus Calmette-Guerin) in a Phase I clinical study [95]. More recently, intravenous in-
jections of HA-GEM were found to be effective at treating a subcutaneous, pancreatic cancer
xenograft [193]. The conjugate, which protected GEM from degradation in the plasma, was ef-
fective at accumulating at the tumor site significantly higher than free GEM, giving motivation
to continue exploring the intravenous administration of HA conjugates.
5.2 Synthesis of GEM prodrugs
To control the relative release rate of DOX and GEM, it was desirable to synthesize con-
jugates of GEM with different release kinetics. Previous reports have shown that amino acid
(ester and amide) prodrugs of GEM hydrolyzed with different kinetics, depending on the size
of the amino acid [196, 197]. Therefore, amino acid prodrugs of GEM were synthesized and
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conjugated to HA to control GEM release, which is similar to previous work done with HA-
PTX conjugates [192].
Based on the fast hydrolysis (t1/2 = 11 h) of a previously reported GEM prodrug, which was
synthesized by conjugating the aromatic amine on GEM to a carboxylic acid [198], amino acids
were conjugated to the amine on GEM to ensure fast releasing GEM prodrugs. To prevent the
formation of GEM-amino acid esters, the alcohols on GEM were BOC protected as previously
reported [133]. After protecting the alcohols on GEM, GEM was conjugated to the carboxylic
acids on BOC protected glycine and valine to form prodrugs with different release kinetics
(Fig. 5.1). After conjugation and purification, the BOC groups were deprotected with TFA.
All chemical steps were monitored with NMR and chemical shifts are listed in Chapter 3.
Figure 5.1: Synthesis scheme for GEM prodrugs: GEM-glycine and GEM-valine.
Interestingly, the UV-vis spectrum of the prodrug changes significantly after conjugating to
the amine group (peak shifts from ∼270 to ∼250 nm), consistent with previous reports [197].
This provided a convenient way to distinguish between GEM and GEM-amino acids prodrugs,
without doing HPLC.
5.3 Synthesis and characterization of HA conjugates
HA-GEM and HA-DOX conjugates were synthesized with different release rates to evalu-
ate the effect of release rate on synergy. GEM prodrugs were conjugated directly to HA with
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carbodiimide chemistry (Fig. 5.2), and the release rate of GEM was dependent upon the amino
acid used to link GEM to HA. DOX was conjugated to HA directly with an amide bond and
with a hydazone bond through an adipic acid dihydrazide linker (Fig. 5.2). HA-DOX-GEM
was synthesized by first conjugating the adipic acid dihydrazide linker, then conjugating the
GEM prodrug, and lastly conjugating DOX. Reaction time and reactant ratio could be adjusted
to manipulate DOX and GEM loading.
Figure 5.2: Synthesis scheme for conjugating drugs to HA with an amide bond making:
GEM-gly-HA, GEM-val-HA, and DOX-HA and the synthesis scheme for conjugating DOX
to HA with a hydrazone bond
Drug loading and vehicle size of each PDC is summarized in Table 5.1. Drug loading up
to 8.9 and 11.9 wt % could be achieved with GEM and DOX, respectively, while maintaining
solubility in PBS. While drug loading is measured with UV absorbance (example spectrum
show in Fig. 5.3), GEM drug loading was also verified with 1H NMR (Fig. 5.4), using the
aromatic protons on GEM-gly ( 7.2 and 8.2 ppm) and the HA methyl protons ( 1.9 ppm). The
degree of loading of ADH was quantified with 1H NMR using the ethylene protons on ADH
( 1.6 and 2.3 ppm) (Fig. 5.4). Consistent with previous reports, DOX loading could not be
quantified with 1H NMR because no aromatic proton signals were observed, most likely due
to DOX remaining in the core of self-assembled HA conjugates [135].
Regardless of GEM loading, HA-GEM conjugates were measured to be 10 nm in diameter
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Figure 5.3: UV absorbance spectrum of DOX-HA hydrazone, GEM-gly-HA, and DOX-GEM-gly-HA
Figure 5.4: 1H NMR of HA conjugates with DOX and GEM (D2O, 600 MHz)
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with DLS with no larger structures observed with cryo TEM (Fig. 5.5). This suggests, that
GEM did not induce any assembly between separate HA-GEM polymers. On the contrary, all
conjugates containing DOX, were measured to be approximately 20 to 100 nm in size with
DLS, which was confirmed with cryo TEM images (Fig. 5.5). As DOX loading was increased,
larger structures (100-200 nm) were evident, suggesting the self-assembly of the conjugates is
due to the hydrophobic nature of DOX.
Figure 5.5: Cryo TEM of (a) GEM-gly-HA, (b) DOX-HA, and (c) DOX-GEM-gly-HA.
Table 5.1: Characterization of drug-HA conjugates
Conjugate DOX loading (wt. %) GEM loading (wt. %) DLS number mean (nm)
DOX-HA amide 1.5 – 10.5 ± 3.0
DOX-HA hydrazone i.) 4.3 – i.) 65 ± 28
ii.) 11.8 – ii.) 106 ± 51
GEM-gly-HA – i.) 3.9 i.) 8.8 ± 2.5
– ii.) 5.7 ii.) 11.7 ± 2.2
GEM-val-HA – 4.0 11.7 ± 2.2
DOX-GEM-gly-HA i.) 2.5 i.) 3.6 i.) 24.8 ± 5.0
ii.) 3.6 ii.) 5.0 ii.) 22.3 ± 5.0
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5.4 Cellular toxicity of HA conjugates
The toxicity of the drug-HA conjugates and the release kinetics of each drug was measured
(Fig. 5.6). Less than 10 % of DOX is released from the DOX-HA amide conjugate after 100 h;
however, approximately 50 % of DOX is hydrolyzed from the DOX-HA hydrazone conjugate.
This release is quicker in acidic pH (t1/2 = 107±11 h (pH 5) vs t1/2 = 141±18 h (pH 7.4)).
The toxicity of the conjugates on MDA-MB-231 cells (Fig. 5.6a) and 4T1 cells (Fig. 5.8)
is reflective of the availability of released DOX, as free DOX is more toxic than DOX-HA
hydrazone which is more toxic than DOX-HA amide. This is also evident by looking at DOX
internalization. After 24 h incubation, the majority of free DOX is inside the nucleus, while
most of the DOX after incubation with DOX-HA hydrazone is still outside of the nucleus, most
likely in endosomes (Fig. 5.7).
While both GEM prodrugs were conjugated to HA with an amide bond, the release rate of
GEM from the construct is different based on the amino acid used to conjugate GEM to HA.
GEM is hydrolyzed quicker from GEM-gly-HA (t1/2 = 88± 5 h (pH 5), 28 ± 2 h (pH 7.4))
than from GEM-val-HA (t1/2 = 179± 12 h (pH 5), 124 ± 14 h (pH 7.4)) in both neutral and
acidic conditions. Again, the toxicity of the constructs on MDA-MB 231 cells (Fig. 5.6) and
4T1 cells (Fig. 5.8) is correlated with the availability of free drug, as free GEM is more toxic
than GEM-gly-HA which is more toxic than GEM-val-HA.
In order to test the hypothesis that a mixture of conjugates which exposes the cells to
GEM prior to DOX is more synergistic than other sequences, the toxicities of different mix-
tures of GEM and DOX conjugates were evaluated on MDA-MB-231 cells. Because DOX is
hydrolyzed extremely slow from DOX-HA amide, as reflected with the minimal toxicity, DOX-
HA hydrazone is used for the remainder of the studies. The toxicities of DOX-HA alone and
physical, equimolar mixtures of DOX-HA with GEM-val-HA, GEM-gly-HA, and free GEM
were evaluated (Fig. 5.10). All equimolar, physical mixtures of DOX-HA with GEM are more
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Figure 5.6: Cell inhibition of MDA-MB-231 cells comparing the toxicity of DOX to
DOX-HA conjugates (a) and GEM to GEM-HA conjugates (b). Cells were incubated for
72 h with formulations and cell viability was measured with the MTT assay. Data repre-
sent mean ± SD (n ≥ 12 wells). Release kinetics of DOX-HA conjugates (c) and GEM-HA
conjugates (d) measured with dialysis. Data represents mean ± SD (n ≥ 3).
toxic than DOX-HA alone due to synergy of the drugs, even though GEM conjugates are min-
imally toxic at this low concentration (Fig. 5.6). In addition, mixtures which contain a form
of GEM that is available relatively faster than DOX (GEM-gly-HA and free GEM) than those
that contain a form of GEM that is released slower than DOX (GEM-val-HA) are more toxic.
DOX-GEM-gly-HA was also synthesized and evaluated because GEM is released relatively
faster than DOX with this combination (Fig. 5.6 and Fig. 5.9). The combination conjugate is
more toxic than the physical mixture of DOX-HA and GEM-gly-HA, most likely due to more
of the drug being internalized due to less overall polymer. The synergy of the combination
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Figure 5.7: Confocal images of DOX and DOX-HA hydrazone internalization after 24 h
incubation with MDA-MB-231 cells (1 µM DOX). Nuclei are stained with Hoechst 33342.
Free DOX is localized into the nucleus while DOX-HA is located primarily outside of the
nucleus.
Figure 5.8: Cell inhibition of 4T1 cells comparing the toxicity of GEM to GEM-gly-HA (a)
and DOX to DOX-HA hydrazone conjugate (b). Cells were incubated for 72 h with formula-
tions and cell viability was measured with the MTT assay. Data represent mean ± SD (n ≥
12 wells)
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conjugate was also verified with a combination index less than 0.5 across a wide range of
toxicities (Fig. 5.10b).
Figure 5.9: Release of DOX and GEM from DOX-GEM-gly-HA measured with dialysis in
PBS at pH 5 and 7.4. Data represents mean ± SD. (n=3)
Figure 5.10: (a) Comparing the concentration of DOX in DOX-HA alone, a physical mixture
of DOX-HA with GEM-val-HA, GEM-gly-HA, or free GEM, and DOX-GEM-gly-HA that
inhibits 50 % MDA-MB-231 cell growth. Cell inhibition was measured with the MTT as-
say after incubating the cells with drug formulations for 72 h. (b) The degree of synergy of
DOX-GEM-gly-HA compared to DOX-HA and GEM-gly-HA calculated with the combina-
tion index. Data represents mean ±95% confidence interval (n ≥ 12 wells).
The cell cycle distribution of MDA-MB-231 cells was also measured after exposure to HA-
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drug conjugates (Fig. 5.11). The cell cycle distribution after exposure to DOX-HA and both
GEM-HA conjugates mimicked the distribution after exposure to the free drugs, discussed in
Chapter 4. After exposure to the physical combination of GEM-gly-HA and DOX-HA and the
combination conjugate DOX-GEM-gly-HA, the cell cycle distribution of the cells mimicked
that of free GEM as well. This is consistent with the cellular response after cells were exposed
to GEM 1 d prior to DOX.
Figure 5.11: Cell cycle distribution (measured with P.I. nuclear staining) after 72 h exposure
to HA-drug conjugates (1 µM).
5.5 In vivo efficacy of HA conjugates
To evaluate the efficacy of the polymer conjugates in vivo, a mouse model with an intact
immune system (orthotopic, 4T1 tumor model) was selected to ensure realistic clearance rates
of the HA carrier. The individual conjugates (DOX-HA and GEM-gly-HA), the free drug com-
bination (DOX+GEM), and the optimal polymer drug conjugate (DOX-GEM-gly-HA) were
all injected i/v every third day (starting 4 days post tumor transplantation) for a total of four
injection cycles. Doses of DOX (2 mg/kg) and GEM (2.75± 0.3 mg/kg) were the same in each
group.
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Figure 5.12: Tumor growth study in an orthotopic, 4T1 tumor model. (a) Tumor growth
curve for DOX-HA, GEM-HA, DOX-GEM-HA, and the physical mixture of DOX and GEM.
The dose for DOX and GEM in each group is 2 and 2.75 ± 0.3 mg/kg, respectively, and 4
total doses were given every 3rd day starting on day 4 post tumor inoculation. (b) Average
body mass throughout the tumor study. (c) Comparison of average tumor size on day 20.
Data represents mean ± SEM (n = 4 for DOX-HA, n = 5 for every other group). Statistical
significance is calculated with students, unpaired t-test.
DOX-HA showed no tumor reduction compared to a control group with no treatment, while
GEM-gly-HA showed significant reduction in tumor size. The free drug combination of DOX
and GEM also reduced tumor size a significant amount; however, the combination drug conju-
gate (DOX-GEM-gly-HA) significantly inhibited more tumor growth (Fig. 5.12). The tumors
in the mice treated with the combination conjugate eventually relapsed after treatment stopped.
Using the low drug doses, no body weight loss was observed for any of the conjugate groups,
but 2 mice treated with the free drug combination suffered greater than 15 % body weight loss.
5.6 Optimization of delivery site and dose
While the majority of polymer drug conjugates are administered intravenously, HA con-
jugates can be administered through various parenteral administration routes because HA is
continuously recycled in many different tissues throughout the body. For example, HA conju-
gates were previously administered peritumorally (with a subcutaneous injection) to effectively
treat mammary tumor xenografts with no observable local inflammation at the injection site
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[134, 113]. By changing the injection site, distribution of the conjugate and tumor exposure to
each drug can be manipulated, impacting tumor regression.
Using the same doses as previously used (2 mg/kg DOX and 2.75 mg/kg GEM), DOX-
GEM-HA conjugates were injected intraveneously, and subcutaneously, in the inguinal mam-
mary gland opposite the tumor and peritumorally. The exact locations of the subcutaneous
injections are shown in Fig. 5.13c, and they were chosen to ensure that the conjugates could
slowly drain into the inguinal and axillary lymph nodes. For each group, dosing frequency was
extended to every 5 d (as opposed to every 3 d), in an attempt to extend mouse survival and to
minimize potential local inflammation at the site of the s/c injections.
Figure 5.13: Tumor growth study in an orthotopic, 4T1 tumor model comparing administra-
tion route of DOX-GEM-HA. (a) Tumor growth curve for DOX-GEM-HA administered i/v
and s/c in the inguinal mammary fat pads peritumorally (local) and bilaterally to the tumor
(non-local). The dose for DOX and GEM in each group is 2 and 2.75 mg/kg, respectively,
and 4 doses were given every 5th day starting on day 4 post tumor inoculation. (b) Average
body mass for each treatment group. (c) Image of inguinal, s/c injection sites relative to tumor
location. Data represents mean ± SEM (n = 5)
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Tumor growth was significantly inhibited in each group, and no body weight loss was
observed for any group (Fig. 5.13a-b). The mice which received local, s/c injections (peri-
tumoral) had the slowest tumor growth, but tumors still relapsed after treatment was stopped.
Interestingly, nonlocal, s/c injections were nearly as effective as i/v injections at inhibiting
tumor growth, indicating that s/c injections can be used to treat cancer systemically. While
no signs of toxicity were observed for the i/v injected mice, a few mice which received s/c
injections showed hair loss near the injection site.
Because serious toxicity was not observed for the conjugate groups, a higher dose of DOX-
GEM-HA was administered in an attempt to completely eradicate the tumors. Due to solubility
limitations, conjugates could not be synthesized with twice as high drug loading without form-
ing large aggregates. A higher s/c injection volume permitted administering DOX-GEM-HA
at twice the dose as previously used (4 mg/kg DOX, 5.5 mg/kg GEM), while still using a con-
jugate with the same drug loading. The injection volume could not be increased for bolus
i/v injections, so DOX-GEM-HA was administered with a higher GEM and lower DOX drug
loading (1 mg/kg DOX, 5 mg/kg GEM).
For the non-local, s/c injections, the higher dose resulted in a significant reduction in tumor
growth (Fig. 5.14). During the injection cycle, the tumors treated with the high dose did not
grow at all, while those treated with the low dose grew at a slow rate. While no major toxicity
was observed for either group, the higher dose injection resulted in more hair loss near the in-
jection site than the low dose injection. For the i/v injection groups, the conjugates with a high
GEM loading inhibited tumor growth more than the conjugates with a lower GEM but higher
DOX loading (Fig. 5.14). Furthermore, tumors treated with DOX-GEM-HA intravenously
(with a high GEM loading) did not relapse until approximately 10 d after the last injection,
which resulted in tumors maintaining a volume below 100 mm3 20 d longer than the tumors
that received no treatment.
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Figure 5.14: Tumor growth study in an orthotopic, 4T1 tumor model comparing dose of
DOX-GEM-HA. (a) Tumor growth curve for DOX-GEM-HA administered i/v and s/c in the
inguinal mammary fat pad bilaterally to the tumor (non-local) at different doses. Doses for
each group are shown in the figure (DOX mg/kg / GEM mg/kg). (b) Average body mass for
each treatment group. Data represents mean ± SEM (n = 5)
5.7 Discussion on HA conjugates
While drug schedule plays a significant role in cellular toxicity when giving GEM and
DOX in bolus sequences in vitro, the impact of schedule upon differential release from a drug
delivery carrier was unknown. To study this, DOX and GEM were conjugated to HA with
varying release rates for proof of principle. Similar to previous reports, DOX was conjugated to
HA with both an acid labile linker and a stable, amide bond [134, 135, 111]. To conjugate GEM
to HA with varying release rates, prodrugs were formed with amino acids, and the bulkiness
of the amino acid controlled the hydrolysis of GEM from HA, similar to previous synthetic
strategies with PTX [199]. Contrary to the DOX conjugation strategies, the ability to control
the release of GEM by performing chemistry on the drug prior to conjugation to the polymer
makes it significantly easier to control the release rate of the drug.
The toxicity of the individual conjugates, relative to free drug, is reflective of the bioavail-
ability of the drug (Fig. 5.6 and 5.8). When combining the conjugates at an equimolar ratio, the
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toxicity significantly increases when GEM is available relatively faster than DOX, as evident
by the decrease in the IC50 of the combination when combining DOX-HA with GEM-val-HA
(3.0 ± 0.4 µM), GEM-gly-HA (2.2 ± 0.2 µM), and free GEM (1.9 ± 0.2 µM). These re-
sults are consistent with the free drug, bolus, scheduling data, showing the benefit of releasing
GEM relatively faster than DOX when giving the two in combination. In addition, the cell
cycle distribution of cells incubated with the optimal combination of conjugates is similar to
that of physically giving GEM to DOX, providing evidence that the cells are being exposed
to the effects of GEM prior to that of DOX (Fig. 5.11). Interestingly, the optimal combi-
nation conjugate DOX-GEM-gly-HA was much more active than the physical mixture of the
two conjugates in vitro, likely due to a slight increase in the release rate of DOX from the
combination conjugate compared to DOX-HA on its own (Fig. 5.9) or due to an increase in
conjugate internalization with DOX-GEM-gly-HA compared to the combination of DOX-HA
and GEM-gly-HA.
The efficacy of the conjugates were tested in vivo in an immune competent, orthotopic 4T1
tumor model. Injecting every 3 d intravenously, the combination conjugate (DOX-GEM-HA)
was effective at stopping tumor growth up to 10 d post treatment, which was significantly more
effective than the individual conjugate treatments (DOX-HA and GEM-HA) and the free drug
combination (DOX+GEM). Although the free drug combination was moderately effective at
inhibiting tumor growth, multiple mice had to be euthanized due to weight loss. No weight loss
was observed for any of the conjugate groups, indicating minimal acute toxicity associated with
the treatments.
Previous studies have shown the benefits of sequentially giving single drug PDCs in vivo
with other chemotherapeutics [130, 129], but a similar therapeutic benefit can be obtained by
conjugating both drugs to the same polymer backbone and controlling the release rate of the
drugs. While it is more difficult to conjugate two drugs to the same polymer, you can control
the exact ratio and schedule that the cells see in vivo by having a single delivery vehicle. This
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can help ensure that cells are sensitized in vivo to a second drug similarly to preliminary in
vitro studies. Controlling the relative release rate of drugs from combination delivery vehi-
cles is something that should be thoroughly studied and controlled in the future to maximize
therapeutic benefit of combination delivery vehicles.
In addition to intravenous injection, HA conjugates have been administered through other
parenteral routes in pre-clinical and clinical studies to alter drug biodistribution. Here, we
show that DOX-GEM-HA can effectively treat 4T1 tumors administered both locally and sub-
cutaneously in inguinal mammary fat pads. While the i/v injections were the most effective
administration route, the ability to still treat with s/c injections opens up a promising area for
future research. It was not surprising that the local, s/c injection was effective at inhibiting
tumor growth, but it was surprising that the non-local s/c injections were almost as effective
as i/v injections at inhibiting tumor growth. This demonstrates that local, s/c injections of HA
conjugates can still be used to effectively treat cancer metastases elsewhere in the body. The
exact mechanism of whether the drug reaches systemic circulation already released from HA,
as a reduced molecular weight HA conjugate, or as the original HA conjugate is currently under
investigation. Previous studies suggest that the HA is being degraded into small HA oligomers
in the lymphatic system prior to entering systemic circulation.
Furthermore, by delivering the conjugates subcutaneously in the mammary fat pads, the
conjugates will drain into the same lymph nodes which are responsible for cancer metastasis.
Previous studies have shown that accumulation of delivery vehicles into the lymph nodes can
prevent future metastasis by killing the tumor cells before they enter systemic circulation. Fu-
ture studies can study how effective DOX-GEM-HA is at preventing cancer metastasis with
highly, metastatic cancer cells lines in vivo.
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Chapter 6
Optimizing delivery of LAP and PTX with
bi-phasic nanoparticles
Lapatinib (LAP) was originally approved for treating late stage, HER2+ breast cancer in com-
bination with capecitabine. Since then, it has been tested in various clinical trials as a substitute
for trastuzumab in combinations with other chemotherapeutic agents. In particular, LAP and
paclitaxel (PTX) have been evaluated for treatment of various phenotypes of metastatic breast
cancer [200, 201, 202, 203, 204]. The addition of LAP to PTX chemotherapy regimens has
extended the survival of patients with metastatic, HER2+ cancer while being mostly ineffective
for HER2- patients [200, 201, 203]. In addition, LAP and PTX have proven to be effective in
treating HER2+ breast cancer patients in the neoadjuvant setting [204]. The use of high doses
of LAP has also been used to increase the delivery of albumin bound PTX to various solid
tumors by reducing the hyperpermeability of the tumor vasculature [205].
Given the early clinical success of PTX and LAP, it is important to ensure that the two
drugs are being administered in an optimal manner. However, designing the optimal combi-
nation regimen for PTX and LAP is a challenge because LAP is given orally while PTX is
administered intravenously with the solubilizing oil Cremaphor EL. To ensure the drugs reach
77
Optimizing delivery of LAP and PTX with bi-phasic nanoparticles Chapter 6
the tumor site simultaneously, various delivery systems have been synthesized to co-deliver the
two hydrophobic agents. In particular, LAP and PTX have been loaded into the core of micelles
[206, 207, 208, 209], liposomes [210], injectable hydrogels [211], and layer by layer nanopar-
ticles [212]. In many of the studies, the combination vehicles were synergistic at inhibiting the
growth of both HER2+ cancer cells and many multi-drug resistant cancer cell lines.
To engineer an optimal carrier and maximize synergy for LAP and PTX, it is advantageous
to control both the molar ratio and drug release kinetics; however, current delivery systems do
not allow for control over release kinetics of each drug. On the contrary, bi-phasic nanopar-
ticles would allow for the drugs to be loaded into distinct compartments which degrade at
different rates. Previously, biphasic nanoparticles have been synthesized with microfluidic and
electrohydrodynamic (EHD) co-jetting processes [213]. In particular, EHD co-jetting has been
used to synthesize particles containing compartments with different physical properties [214].
These particles have been engineered to carry small molecule therapeutics, siRNA, and imag-
ing agents for various therapeutic applications [215, 216, 217]. In addition, the particles can
be synthesized as less than 200 nm, allowing for extended circulation [218, 219].
While current delivery platforms are effective at deliverying LAP and PTX in combination,
the release rate of each drug from the delivery platforms is governed by the physical structure
of the vehicles. Further efficacy may be achieved by optimizing the sequence and ratio in which
the drugs are administered. Previously, pretreatment with trastuzumab (which also inhibits the
HER2 receptor) prior to PTX was more effective at initiating apoptosis in HER2+ cancer cells
than the simultaneous exposure of the two agents. However, there is no way to manipulate
the relative release rates of the drugs from the current delivery platforms. Therefore, we have
designed a novel, bi-phasic polymeric nanoparticle delivery system to allow for the drugs to
release at different rates. The particles are synthesized with EDH co-jetting, and the toxicities
of different particle systems are compared.
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6.1 Synergy of LAP and PTX in BT-474 cells
Using BT-474 cells as a representative cell line for HER2+ breast cancer, the toxicity of
both LAP and PTX were determined for different drug exposure times (Fig. 6.1). The 72 h
IC50 doses for PTX and LAP were determined to be 14±1 nM and 85±10 nM, respectively.
Decreasing the exposure time of each drug from 72 h to 24 h increased the IC50 dose 6x and
3x for PTX and LAP, respectively. On the contrary, delaying the exposure of PTX and LAP for
24 h increased the IC50 dose approximately 3x for both drugs.
Figure 6.1: Fractional cell inhibition and relevant dose response curves for BT-474 cells after
exposure to (a) LAP→ media (b) media→ LAP (c) PTX→ media (d) media→ PTX. Cell
viability was assessed at 72 h for each schedule. Error bars represent 95 % CI (n ≥ 12 wells).
After identifying the relative toxicity of each drug on its own, cellular proliferation was
measured after exposure to combinations of LAP and PTX. Using a fixed molar ratio of 3:1
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(LAP:PTX), near the IC50 of each drug, the cells were exposed to different schedules of drugs
(Fig. 6.2a). Given the cell viability after exposure to the individual drugs compared to the
combination treatments (Fig 6.2b), it was determined that giving LAP 4h prior to PTX is sig-
nificantly more synergistic than giving the two drugs simultaneously (Fig 6.2c). This is true if
you leave LAP present after PTX exposure or if you remove extracellular LAP after PTX expo-
sure. In addition, it is also synergistic if you give PTX prior to LAP; however, the combination
is not as toxic as exposing the cells to LAP first.
Figure 6.2: Toxicity as a function of different schedules of LAP (0.03 µM) and PTX (0.01
µM) on BT-474 cells (a) 72 h incubation schedule of LAP and PTX. (b) Fractional cell in-
hibition as a function of different LAP and PTX schedules evaluated with MTT assay. (c)
Combination index as a function of schedule. (Error bars represent 95% confidence intervals
(n ± 6 wells))
Using the optimal schedule of LAP (4 h)→ PTX/LAP (68 h), the effect of molar ratio on
synergy between LAP and PTX was studied. With a PTX dose below the IC50 (0.10 µM),
molar ratios of LAP:PTX greater than 1 are synergistic (CI < 1). However, as you increase
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the dose of PTX significantly above the IC50 (0.30 µM), the synergy is less than at lower PTX
doses. This is likely due to the fact that at this high concentration, PTX is already significantly
toxic on its own.
Figure 6.3: Synergy as a function of LAP:PTX molar ratio when exposing cells to LAP (4 h)
→ LAP/PTX (68 h) (Error bars represent 95% confidence intervals (n ≥ 12 wells))
6.2 Synthesis of bi-phasic nanoparticles with LAP and PTX
Bi-phasic spherical nanoparticles were synthesized with EHD co-jetting [214]. Briefly, two
polymeric solutions flow through a needle under laminar flow conditions. An electric field is
applied and the droplet at the tip of the needle breaks into a thin thread. The thread breaks into
small droplets, and the solvent quickly evaporates, leaving behind polymeric nanoparticles.
Becuase the fluid flow had two laminar streams, the resulting particle can contain multiple
compartments. Fig. 6.4 shows a cartoon schematic of the process.
Both LAP and PTX were loaded into single bi-phasic nanoparticles by including the drugs
in the polymeric solutions. By incorporating each drug into different compartments, particles
with differential drug release kinetics could be obtained. Particles have an average size of 160
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Figure 6.4: Cartoon schematic of EHD process used to fabricate bi-phasic nanoparticles.
Reprinted from [216] with permission from Wiley.
nm with low polydispersity (Fig. 6.5). The bi-phasic structure of the particles was verified
with SIMS by loading different fluorescent molecules into each of the polymer phases in the
nanoparticles (PLGA and PLGA/AcDEX).
To demonstrate the difference in degradation of each of the polymer phases, Rhodamine
B was incorporated into the AcDEX/PLGA compartment and Coumarin into the PLGA com-
partment. The release kinetics of each fluorescent molecule was measured with dialysis and
fluorimetry. The stability of both polymer phases was evident by the slow release kinetics of
the fluorescent molecules at pH 7.4 (Fig 6.6a). At pH 5, the release of Rhodamine B from
the AcDEX/PLGA compartment phase of the nanoparticles is significantly faster than that of
Coumarin from the PLGA compartment. (Fig 6.6c). This was also evident after changing the
pH of the solution from pH 7.4 to pH 5 (Fig 6.6b). The quick release from the acetylated
dextran phase in acidic pH compared to neutral pH is clearly shown in Fig 6.6d.
After establishing that the AcDEX/PLGA compartment releases fluorescent dyes faster
than the PLGA compartment, biphasic nanoparticles were co-jetted with LAP and PTX. The
82
Optimizing delivery of LAP and PTX with bi-phasic nanoparticles Chapter 6
Figure 6.5: SEM image (a) and relevant particle size distribution (b) of co-jetted, pH respon-
sive Janus nanoparticles (Mean diameter: 166 ± 61.2 nm, Scale bar, 1 µm). (c) Super-res-
olution images of dye-loaded Janus nanoparticles with Structured Illumination Microscopy
(SIM) demonstrating their biphasic architecture (Scale bar, 200 nm). (d) Dynamic Light
Scattering (DLS) measurement. Estimated mean hydrodynamic diameter is 240 ± 47 nm.
drugs were loaded into different compartments to change the releative relase rate of each drug
(Table 6.1). Control particles were also made with just a single drug or no drug. While each
particle system was jetted with LAP and PTX concentrations to give final drug loadings of 2.7
and 5.5 wt. %, respectively, approximately a 4-fold lower drug loading remained after washing
each particle type, determined with HPLC (Table 6.1).
Prior to determining how effective the drug loaded particles were at inhibiting cancer cell
growth, the toxicity of the blank particles were determined on MDA-MB-231 cells and BT-474
cells (Fig. 6.7). Up to a particle concentration of 3 µg/mL, no toxicity was observed for the
blank particles. Higher concentrations of the particles were not evaluated because these particle
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Figure 6.6: Release of Coumarin 314 and Rhodamine B dyes from PLGA and PLGA/AcDex
compartments: (a) Extended cumulative release at physiological pH 7.4. (b) pH responsive
release following pH change from 7.4 to 5.0 at 24 h time point. (c) Cumulative release during
first 24 h at pH 5.0. (d) Release of Rhodamine B from pH responsive compartment at pH 7.4
and 5.0.
Table 6.1: Synthesis of biphasic nanoparticles with different loadings of PTX and LAP
Particle Name AcDEX/PLGA comp. PLGA comp. PTX (wt. %) LAP (wt. %)
P1 LAP PTX 0.71 1.24
P2 LAP + PTX – 0.65 1.29
P3 PTX LAP ∼0.7 ∼1.2
PTX control – PTX 0.76 –
LAP control LAP – – ∼1.2
Blank – – – –
concentrations were sufficiently high for toxicity testing with the drug loaded particles.
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Figure 6.7: Fractional cell inhibition of MDA-MB-231 and BT-474 cells after 72 h exposure
of blank bi-phasic nanoparticles. Error bars represent 95 % CI (n ≥ 6 wells).
6.3 Growth inhibition of HER2+ breast cancer cells
The toxicity of each combination biphasic nanoparticle was evaluated on BT-474 cells (Fig.
6.8). The biphasic particles which contained LAP in the AcDEX/PLGA compartment and PTX
in the PLGA compartment induced the most cellular toxicity of the particles loaded with both
drugs. Both particles which contained PTX and LAP in different compartments (P1 and P3),
have a lower PTX IC50 (2.2± 0.4 nM and 7.8± 0.9 nM, respectively) than free PTX (14± 1
nM). Interestingly, the particle system which contained both drugs in the AcDEX/PLGA com-
partment (P2), is not as toxic as free PTX. All combination particle systems are significantly
more toxic than free LAP at the concentrations tested.
The cellular toxicity of the most toxic combination vehicle (P1) was compared to single
drug loaded particles with LAP and PTX in the AcDEX/PLGA and PLGA compartments,
respectively. The dual loaded particle (P1) was considerably more toxic than both the PTX and
LAP control particles (Fig. 6.9), which had similar drug loadings to the dual loaded particle
(Table 6.1). In addition, the dual loaded particle (P1) is much more effective at inhibiting
85
Optimizing delivery of LAP and PTX with bi-phasic nanoparticles Chapter 6
Figure 6.8: (a) Fractional cell inhibition of BT-474 cells after 72 h exposure to the following
bi-phasic particles: P1 (AcDEX/PLGA: LAP, PLGA: PTX), P2 (AcDEX/PLGA: LAP + PTX,
PLGA: blank), and P3 (AcDEX/PLGA: PTX, PLGA: LAP) Points are experimental data and
lines are best fit median effect model. (b) PTX IC50 concentrations for each particle type.
Error bars represent 95 % CI (n ≥ 12 wells)
Figure 6.9: (a) Fractional cell inhibition of BT-474 cells after 72 h exposure to the fol-
lowing bi-phasic particles: LAP control (AcDEX/PLGA: LAP, PLGA: blank), PTX control
(AcDEX/PLGA: blank, PLGA: PTX), LAP control + PTX control, and P1 (AcDEX/PLGA:
LAP, PLGA: PTX) Points are experimental data and lines are best fit median effect model.
(b) Combination index (CI) for particle P1. Error bars represent 95 % CI (n ≥ 6 wells).
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BT-474 cell growth than a physical mixture of LAP and PTX control particles at similar drug
concentration. Compared to the single drug loaded particles, the dual loaded particles are
synergistic at inhibiting cell growth (CI < 0.5) for particle concentrations less than 1 µg/mL
(Fig. 6.9b).
6.4 Extension to HER2- breast cancer cells
The toxicity of the bi-phasic nanoparticles was also evaluated on triple negative breast
cancer cells (MDA-MB-231). Because triple negative cells are HER2-, LAP is ineffective at
inhibiting MDA-MB-231 growth. Using LAP concentrations which are relevant to the particle
systems (up to 100 nM), LAP does not inhibit any MDA-MB-231 growth. However, LAP has
shown to enhance the toxicity of other cytotoxic drugs on HER2- cancer cells by inhibiting
drug efflux pumps [220, 221].
Figure 6.10: (a) Fractional cell inhibition of MDA-MB-231 cells after 72 h exposure to the
following bi-phasic particles: LAP control, PTX control, P1, and P2. Points are experimental
data and lines are best fit median effect model. (b) PTX IC50 concentrations for each particle
type. Error bars represent 95 % CI (n ≥ 12 wells).
Interestingly, both dual loaded particle systems are more toxic than the single loaded PTX
particles on MDA-MB-231 cells, even though the single loaded LAP particles show no signs
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of toxicity (Fig. 6.10). The IC50 for the dual loaded particles P1 and P2 is 3x and 2x lower,
respectively, than the single loaded PTX particles. In addition, the most toxic dual loaded
particle (P1) has a significantly lower IC50 than free PTX (P1: 4.3±0.6 nM, free PTX: 11±2
nM).
6.5 Discussion on LAP/PTX bi-phasic nanoparticle system
LAP has been used in combination with many other chemotherapeutics in the clinic due
to its ability to enhance tumor inhibition. In particular the combination of LAP and PTX has
proven to be an effective drug combination for treating late stage, metastatic breast cancer.
Here, we show that the drug pair is synergistic at inhibiting the growth of HER2+ breast cancer
cells only if given in the correct sequence. We then demonstrate that we can synthesize bi-
phasic nanoparticles which are capable of controlling both the molar ratio of LAP and PTX
and the relative release rate of each drug.
The HER2+ cell line BT-474 is responsive to both LAP and PTX with single drug IC50
values in the nM range; however, the combination of LAP and PTX is not synergistic if the
cells are exposed to both drugs simultaneously defeating the purpose of combining the two
drugs. If the schedule of drug administration is tweaked, such that the one drug is exposed
prior to the other drug, the combination becomes synergistic indicating a lower drug dose can
be administered to achieve the same cellular growth inhibition. Synergy is the highest when
LAP is given 4 h prior to PTX at a molar ratio of LAP:PTX of 3:1. For the optimal schedule,
the combination index (CI) is approximately 0.5, indicating that a 2x fold lower dose of PTX
can be given. It is evident that synergy between LAP and PTX is highly dependent upon both
the schedule and molar ratio of LAP and PTX while treating BT-474 cells. This is consistent
with a previous study which showed that trastuzumab can only enhance the toxicity of PTX on
HER2+ cancer cells if the cells are exposed to trastuzumab first [222].
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The strong dependence of drug ratio and schedule on drug synergy, makes it difficult to
translate an effective combination dosing regime to the clinic due to the complicated phar-
macokinetics of each drug. Various nano-sized delivery vehicles have been synthesized to
carry both LAP and PTX to ensure that cancer cells are exposed to the drugs simultaneously;
however, drug release from these vehicles cannot be changed without changing the physical
structure of the vehicle and/or drug loading process [206, 207, 208, 209, 210, 211, 212]. Here,
we used EHD co-jetting to synthesize biphasic nanoparticles which enable us to manipulate
the release rate and molar ratio of drug-loaded particles without drastically changing the drug
loading technique and/or overall particle structure.
Biphasic nanoparticles were synthesized with one compartment containing AcDEX/PLGA
and one compartment containing PLGA. The particles are less than 200 nm, ideal for extended
particle circulation and accumulation in tumors with leaky vasculature. The biphasic morphol-
ogy of the nanoparticles was verified with SIMS, and each compartment degrades and releases
fluorescent dye at a different rate. The AcDEX/PLGA compartment is pH responsive and de-
grades significantly faster in acidic pH than the PLGA compartment. It is expected that the
drugs which are loaded into the AcDEX/PLGA compartment will be available to the cell faster
than drugs loaded in the PLGA compartment, due to the acidic environment in endosomes
and lysosomes. Furthermore, while not shown here, the composition of the AcDEX/PLGA
compartment can also be manipulated to further tweak the relative release rate of each com-
partment.
Both LAP and PTX could be loaded into either particle compartment, so dual loaded par-
ticles were synthesized varying which compartment each drug was loaded in. Particles which
contained LAP in the AcDEX/PLGA compartment and PTX in the PLGA compartment were
considerably more toxic to BT-474 cells than the particles which contained both LAP and PTX
in the AcDEX/PLGA compartment. This is consistent with the free drug data, which shows
that exposing BT-474 cells to LAP prior to PTX is more synergistic than exposing the cells
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to both drugs concurrently. Furthermore, the dual loaded particles were more toxic than the
single drug loaded particles at the same drug dose, demonstrating that synergy is maintained
between PTX and LAP. Surprisingly, the dual drug loaded particles were also more toxic to
triple negative breast cancer cells (MDA-MB-231), even though the cells are unresponsive to
LAP on its own. The enhanced toxicity is likely due to the inhibition of efflux drug pumps with
LAP [220, 221]; however, further research is required to explore this effect in detail.
The main advantage of using dual drug loaded particles is that cells are exposed to the
drug pair simultaneously in vivo, regardless of how the individual drugs distribute in the body.
However, it is often advantageous to expose the cells to one drug prior to the other drug. Here,
the therapeutic activity of dual loaded PTX/LAP particles could be manipulated in vitro by
changing the relative release kinetics of the drug pair by changing which compartment the
particles were incorporated into. The ability to manipulate individual drug release kinetics,
provides another adjustable parameter while designing combination drug particles. Previous
studies have synthesized core-shell particles to release one drug relatively faster than another
drug; however many of these systems rely on differences in drug hydrophobicity to load into
different regions of the particle [65, 66, 67, 68, 69]. On the contrary, by using EHD co-jetting,
the relative release rate of PTX and LAP, and the resulting cellular toxicity, could easily be
manipulated by changing jetting conditions.
While the dual loaded particles containing LAP in the AcDEX/PLGA compartment were
most effective at inhibiting cancer cell growth in vitro on BT-474 cells and MDA-MB-231
cells, this will not be true for all cell lines. Furthermore, other pairs of chemotherapeutic agents
will demonstrate schedule-dependence, motivating the development of new delivery platforms
capable of controlling the release rate of multiple therapeutics. Moving forward, the effect of
drug release needs to not only be evaluated with respect to cancer cell toxicity in vitro, but also
with respect to healthy cell toxicity and in vivo efficacy. Regardless of the drug combination,
the effect of drug schedule should be critically evaluated when designing a delivery vehicle to
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carry multiple agents.
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Chapter 7
Development of microfluidic technique to
measure local solute concentrations
The focus of the work in this chapter was to develop a new microfluidic technique, capable of
measuring solute concentration with high spatial and temporal resolution. Both the resolution
and the precision of the technique are characterized with standard microfluidic experiments,
to offer insight into the physical systems the technique can be used to probe in future studies.
Furthermore, the utility of the technique is demonstrated by measuring solute transport.
7.1 Microfluidic techniques to measure solute concentration
The field of microfluidics continues to grow as novel microfluidic tools are developed,
offering solutions to a broad range of scientific and technical problems and applications. Re-
cent advances have enabled the rapid generation of complex chemical environments, such as
well defined gradients (e.g. for fundamental chemotaxis studies and high throughput screens
of chemical reaction conditions) [223, 224, 225, 226, 227, 228]. Unfortunately, few general
methods exist to measure the dynamic chemical profiles in situ in microfluidic devices.
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Many techniques have been developed to generate chemical gradients on the micro scale.
One of the most common is to generate gradients with repeated T-junctions of miscible fluids
[229, 230, 231]. Although the technique allows for the design of gradients with various shapes,
drawbacks include the need to precisely control the pressure of each inlet stream and that the
gradient is developed in laminar flow streams. Recently, new methods were developed to
generate chemical gradients with diffusive transport, eliminating convection in the region of
interest [232, 233, 234, 235, 236, 237, 238, 239]. The technique entails having a microchip with
a closed dialysis chamber (CDC), isolated from a source and sink channel by gel membranes
that allow for solute diffusion. CDCs allow both fast chemical switching and rapid generation
of complex chemical gradients due to small length scales [239, 235, 234, 233].
With continued advancements in microfluidic gradient generation, the need to measure
these concentration fields in situ increases. For example, the dynamics involved in develop-
ing a chemical gradient in a CDC requires knowledge of the transport processes involved in
the dialysis membranes and in the CDC, which will be species specific. A general method to
measure concentration fields in situ would facilitate the quantification of transport processes in
the exact experimental system. Moreover, many systems of scientific, industrial, and techno-
logical relevance involve time-dependent processes in which materials precipitate, crystallize,
dissolve, react, or equilibrate. Such processes, in turn, involve spatio-temporally evolving con-
centration fields of solute and solvent. Unfortunately, there is a lack of reliable and general
methods to measure spatial concentration profiles in situ.
In microfluidic systems, fluorescence microscopy is commonly used to measure the spa-
tial concentration profile of chemicals. Although the technique is quick and easy to set up,
chemicals must be tagged with a fluorophore, potentially affecting their function and transport
properties; moreover, photo bleaching can lead to erroneous measurements. Other techniques
have been adapted to microsystems, including Raman spectroscopy [240, 241, 242], Fourier
transform infrared (FT-IR) spectroscopy [243], and Coherent Anti-Stokes Raman scattering
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(CARS) microscopy [244], allowing for the spatial visualization of chemical species without
fluorescent labeling. In particular, Schafer et al have resolved 3D concentration profiles with
sub-µm resolution using CARS microscopy; however, minutes are required to resolve concen-
tration gradients over ∼ 100µm [244]. On the contrary, Chan et al resolved multiple chemical
concentration profiles over multiple millimeters in seconds with FT-IR spectroscopy; however,
the technique only has a lateral resolution of 40 µm [243].
Refractive index measurements provide another strategy to measure concentration profiles.
Various interferometric techniques have been adapted to microfluidic systems to precisely mea-
sure the average refractive index of a single (as low as ∼ µm3) point in space, down to 10−4
to 10−7 RIU, including a mach-zender interferometer [245], a back scattering interferometer
[246], a Young interferometer [247], and Fabry-Perot interferometers [248, 249, 250]. To our
knowledge, only one refractometry method, consisting of a Fabry-Perot interferometer with a
monochromator, is able to resolve spatial refractive index profiles in a fluidic system [251].
This technique is optimized for measurements in nanofluidic channels and not immediately
applicable to measuring evolving concentration profiles in microfluidic channels.
Here we demonstrate a Fabry-Perot interferometric system designed to measure the local
concentration of chemical species in microchannels with or without flow. Fabrication of the
Fabry-Perot chip is relatively simple, and the Fringes of Equal Chromatic Order (FECO) are
generated directly on an inverted microscope and imaged with a spectrometer and CCD camera,
enabling the technique to be easily utilized to study various transport processes in microfluidic
devices. By following the displacement of the FECO fringes, we resolve changes in refractive
index down to 2× 10−5 RIU. A spatially resolved spectrometer enables the local refractive
index to be measured with 1 µm resolution. The temporal resolution on each measurement is
∼ 0.05s and is only limited by the sensitivity of the camera.
We first describe the fabrication of the interferometer and the experimental methods used
to track the FECO fringes. We then discuss the spatial and temporal resolution and precision of
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the refractrometry method by looking at the concentration of chemicals in rectangular channels
with homogenous concentrations. Lastly, we use the technique to measure the diffusive evo-
lution of chemical gradients in microfluidic channels to measure binary diffusion coefficients
and concentration dependence and to track the evolution of chemical gradients in CDCs.
7.2 Fabry-Perot microfluidic interferometer development
Here we describe the fabrication of the microfluidic interferometer chip, the acquisition of
FECO fringes, and the image analysis used to determine refractive index as a function of space
and time.
7.2.1 Microfluidic chip fabrication
A microfluidic device consisting of a single, 90 µm layer between semi-reflective glass sur-
faces was fabricated (Fig. 7.1). After drilling inlet holes into one of the glass slides, electron-
beam evaporation (SEC600, CHA, Industries) was used to deposit a 5 nm adhesion layer of
Ti and 50 nm layer of Ag onto the glass slides to make them semi reflective. Oxidation of the
silver layer (which can reduce the performance of the device due to a decrease in finesse) was
observed over a few days; however, this can be delayed if a longer lifetime is desired by storing
devices under vacuum when not in use or by depositing a protective SiO2 layer [251]. Even
with oxidation, devices still performed effectively weeks after fabrication.
A laser cutter (Trotec Speedy 100) was used to cut channels into the double sided tape
(Permanent Double Sided Tape, Scotch), which was then sandwiched between the two glass
slides by applying pressure. While the laser cutter allows for any tape design with feature
sizes down to 100 µm, smaller features are possible with standard lithography techniques, if
necessary. PDMS inlets were then ozone bonded to the top glass slide to hold inlet and outlet
tubing. The device was then baked at 80 ◦C for at least 4 hours to strengthen bonding.
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Scotch Tape 
Figure 7.1: Diagram of light path in microfluidic, Fabry-Perot interferometer.
7.2.2 Multiple beam FECO interferometry
FECO interferometry, which is used to simultaneously measure film thickness and refrac-
tive index in the surface forces apparatus (SFA), was used to measure spatial refractive index
profiles [252]. An inverted microscope was used to focus white light on the device from above.
The semi-reflective surfaces allow for constructive and deconstructive interference within the
device, and the transmitted light was focused onto a spectrometer slit with a microscope objec-
tive (Fig. 7.1). The spectrometer (Shamrock series 300, 600 lines/mm grating) was connected
to the outlet of the microscope and a CCD camera (Andor Luca-R) was used to gather images
from the spectrometer (Fig. 7.2a). The horizontal axis in each image corresponds to the phys-
ical dimension in which light is obtained in the slit, while the vertical axis corresponds to the
wavelength of diffracted light.
Due to the superposition of light waves which are reflecting between the two semi-reflective
surfaces, the intensity of transmitted light though the interferometer is dependent on wave-
length and the optical path. The intensity of transmitted light (It) through a one-layer multiple
beam interferometer can be related to the intensity of normal incident light (I0) via the Airy
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Figure 7.2: (a) Image of FECO fringes generated with microfluidic chip (see Fig. 7.5 for
image of microfluidic chip). (b) Light intensity profile (taken at position shown in (a)) as a
function of wavelength demonstrating Gaussian fitting to FECO fringe locations. (c) Wave-
length of FECO fringes from (a) as a function of chromatic order fit to Eqn 7.2. (d) Shift
in FECO fringe location due to diffusion of ethanol from the left (See Fig. 7.4 for image of
microfluidic chip).
Function [253]:
It = I0
[
1
1+( 2r1−r2 )
2 sin2(2pindλ )
]
(7.1)
where n is the refractive index of the layer, r the reflection coefficient of the mirrors, d the
distance between the two reflective surfaces, and λ the wavelength of the incident light.
Fringes are observed at wavelengths of light which produce a maximum in transmitted
light:
λFm =
2nd
m
(7.2)
where m represents the chromatic order of the fringe. The refractive index can be deter-
mined from Eqn. 7.2 with the distance between the reflective surfaces and the wavelengths of
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two Fringes of Equal Chromatic Order (FECO) with unknown successive chromatic orders m
and m+1:
n =
( 1
2d
) λFmλFm+1
λFm −λFm+1
. (7.3)
Although the thickness of the microfluidic channel is not known with high precision, the
absolute refractive index can still be determined with Eqn. 7.3. The thickness of the channel
can be calculated by calibrating with a liquid of known refractive index. Using this method,
the error in a refractive index measurement (δn) scales with the error in the measurement of
FECO fringe wavelength (δλ ) with δnn ∼ ( dλ )(δλλ ). Here, the error in measuring the wavelength
of a fringe is approximately limited by the resolution of the spectrometer and camera (δλ ∼
0.05 nm), giving a refractive index precision of approximately 10−2 RIU .
In order to measure small changes in concentration, a much greater precision in refractive
index is required. Relative shifts in refractive index over time (t0 to t) can be determined with
higher precision than the absolute refractive index, by using Eqn. 7.2 to track the relative shift
of individual fringes:
n(t) = n(t0)
λFm (t)
λFm (t0)
. (7.4)
Here, knowledge of the initial refractive index is required, but no calibration is needed.
With this method, the error in the measurement of refractive index scales with δnn ∼ (δλλ ).
Therefore, the refractive index can be determined with a precision of approximately 10−4RIU
(a subpixel method improves the precision to 2× 10−5RIU). It is interesting to note that the
thickness of the channel does not affect the precision; however, there are limitations on channel
thickness. A channel taller than ∼ 1mm makes it difficult to resolve individual fringes, while a
channel shorter than ∼wavelength of light will not produce any fringes.
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7.2.3 FECO fringe acquisition
Refractive index profiles were determined using Eqn. 7.4. The initial refractive index of
the system was known for each experiment; therefore, only the peak wavelength of a FECO
fringe is required to determine dynamic refractive index profiles. Images of the interferometric
patterns were acquired at each time step, and the wavelengths of FECO fringes were tracked
over time with image analysis.
The wavelength-dependent, transmitted light intensity profile was measured for each hori-
zontal pixel, which corresponds to a specific point in space. A custom-written MATLAB code
located the initial location of FECO fringes by finding the location of local light maxima. Im-
proved resolution for the FECO fringe locations was then obtained by approximating the Airy
Function (Eqn. 7.1) as a series of Gaussian peaks (Fig. 7.2b). To verify that FECO fringes are
being observed, the wavelengths of the fringes from Fig. 7.2b are plotted against successive
chromatic orders (Fig. 7.2c), and found to agree with Eqn 7.2.
After identifying the initial location of the FECO fringes, the fringes were tracked at each
point in space and time. Averaging the relative shift in wavelength of at least 5 fringes, a spatio-
temporal refractive index profile was calculated by applying Eqn. 7.4. Refractive index profiles
were then converted to concentration profiles using previously measured refractive index data
in the CRC Handbook [254]. Fig. 7.2d shows example FECO fringes shifting due to diffusion
of ethanol.
7.3 Characterization of technique
We now discuss the precision, accuracy, and resolution of measuring changes in refractive
index. Fundamentally, the interferometry method is limited by the ability to precisely detect the
position of the FECO fringes. Here, the accuracy and precision of the technique is independent
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of the distance between the two reflective surfaces as long as the refractive index is homogenous
in the optical path. Although no calibration is required, the initial refractive index must be
known to determine the refractive index at a later time.
The noise associated with a refractive index measurement is proportional to the relative
noise associated in identifying a fringe wavelength. When imaging with the camera and spec-
trometer grating previously described, each pixel corresponds to a wavelength of 0.04 nm.
A FECO fringe shift of 0.04 nm corresponds to a shift of ∼ 10−4 RIU in water. By fitting
each fringe with a Gaussian function and averaging relative shifts in wavelength over multiple
fringes, we obtain sub-pixel resolution.
To estimate the precision of fringe detection, static images of pure water were taken. The er-
ror in fringe position was determined by finding the standard deviation of the average difference
between each fringe position and the respective mean fringe position, averaged over 5 fringes.
For long exposure times (> 1s), the refractive index shift precision plateaus at 1.8×10−5 RIU
(Fig. 7.3a). When the exposure time is reduced, the signal to noise ratio decreases, decreasing
the precision of the technique (Fig. 7.3a). However, even with an exposure time as short as
50 ms, the precision in refractive index remained less than 10−4 RIU, indicating that transient
processes with time scales of 50 ms can be tracked.
Small measurement drifts are observed during long experiments (> 10 min). To quantify
the drift, the refractive index of flowing water and stagnant air was measured over a day, at
multiple positions in a microfluidic channel. The measurement can homogeneously increase or
decrease up to ∼ 10−4 RIU/h during the day and night, respectively, throughout the microflu-
idic channel (Fig. 7.3a, inset). These observations suggest that the drift is due to temperature
fluctuations leading to expansion/compression of the whole tape layer. For this paper, all mea-
surements were taken within 10 min and the drift was negligible; however, the small drift can
be corrected for by measuring the refractive index of a static solution during the course of the
experiment.
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Figure 7.3: (a) Error in refractive index measurement over 30 frames in a rectangular channel
with water. Data is expressed as the standard deviation of the average relative fringe shift
(averaged over 5 fringes). (Inset) Example drifts in the refractive index measurements of water
due to temperature fluctuations. Colors represent 5 different positions across the channel. (b)
Experimental fringe shifts when switching from water to solute with a defined concentration
compared to theoretical switch predicted with Eqn 4 and refractive index data [254]. Data is
expressed as mean ± SD (n = 20 fringes).
The spatial resolution of the technique depends on the objective. With a 4x objective, the
pixel size gives a spatial resolution of 1.91µm. As with all light microscopy applications, the
spatial resolution is limited by diffraction, placing a limit of ∼ 1µm on the spatial resolution.
To confirm the accuracy of the technique, fringe positions were tracked while changing
the refractive index of a solution in a rectangular channel by switching from pure water to a
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homogenous mixture of glycerol or ethanol (Fig. 7.3b). The measured refractive index shift
agrees with literature for refractive index shifts greater than that of 0.05%(w/w) glycerol [254].
This is consistent with the previously measured precision (Fig. 7.3a). Furthermore, we studied
the reproducibility of the method by measuring the refractive index shift from water to glycerol
with three repeat trials per microchip on multiple chips. The error of the measured refractive
index shifts between trials on one device and between different devices (2×10−5 RIU) is the
same as the precision of the technique, indicating excellent reproducibility.
Measurement improvements are possible for both refractive index and temporal resolution.
The location of each FECO fringe can be found with higher precision by increasing the reso-
lution of the spectrometer grating or the camera, allowing for a smaller shift in the fringe to
be measured. The combination of a faster camera and a brighter light source can improve the
temporal resolution of the technique by lowering the required exposure time to detect FECO
fringes.
7.4 Measurement of binary diffusion coefficients
We now use the interferometer to monitor the diffusive evolution of chemical gradients.
Experimental techniques used to generate and measure the chemical gradients are discussed.
A numerical model is then compared to the experimental data to extract binary diffusivities in
both free solution and PEG-DA hydrogels.
7.4.1 Experimental design
A microfluidic chip, allowing for the semi-infinite propagation of a diffusive front was
fabricated as shown in Fig. 7.4a. PEG-DA hydrogels are used to isolate channels with flow
from stagnant channels [234]. The hydrogels allow for the generation of diffusive chemical
gradients, by being permeable to diffusive transport but impermeable to convection.
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Figure 7.4: (a) Microfluidic channel geometry for diffusivity measurements. (b) Microscopic
image of photopolymerized PEG-DA gel and region for diffusivity measurements. (c) Ex-
perimentally measured evolution of glycerol diffusive front compared to numerical diffusion
model. (d) Extraction of effective diffusivity in PEG-DA hydrogels with numerical model.
The PEG-DA hydrogels were polymerized in situ using microscope projection lithography
[234]. The aqueous precursor solution consisted of 40% (v/v) PEG-DA-DA 600 (n=400, Poly-
sciences Inc.) and 5% (v/v) photoinitiator (2-hydroxy-2methylpropiophenone, Sigma Aldrich),
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and was exposed with 40 mW ultraviolent light through a 500 µm slit with a 10x objective for
500 ms. Here, the width of the PEG-DA hydrogels are much wider than those made by Paustian
et al.; however, thinner gels could have been fabricated to allow for faster diffusive switching
[234].
7.4.2 Diffusivity measurements in water
To measure binary diffusivities in water, the device was initially filled completely with
water, and flow to the measurement region was stopped with tubing clamps. By changing inlet
tubing, flow to the side channel was switched from water to various solutes at 30% (w/w). After
performing the chemical switch, interferometry was used to track the evolution of the chemical
gradient (Fig. 7.4b). Images of the interferometry pattern were acquired with 1s exposure
time, and FECO fringe displacements were tracked over time to determine the relative shift
in refractive index as a function of position. The refractive index shifts were then converted
to concentrations using Eqn. 7.4, the known initial concentration, and concentration versus
refractive index data [254].
Least squares regression and a numerical diffusion model (Eqn. 7.5) were used to extract
diffusivities and their concentration dependence. A linear relationship between concentration
and diffusivity was assumed based on the solutes and concentration ranges used in the study
(Eqn 7.6) [255, 256, 257, 258, 259, 260].
∂C(x, t)
∂ t
=
∂
∂x
(
D(C(x, t))
∂C(x, t)
∂x
)
(7.5)
D(C) = D0(1−bC) (7.6)
One boundary condition was provided by the measured concentration just outside the hy-
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Table 7.1: Literature and experimentally measured binary diffusivity in water D0, concentra-
tion dependent factor b (Eqn. 7.6), and effective diffusivity parameter k in PEG-DA hydrogels
(Eqn. 7.7).
Literature values Measured values Measured values
Species D0×105 / (cm2/s) b / (1/M) D0×105 / (cm2/s) b / (1/M) k
Glycerol 0.99 [255] 0.08 [255] 0.90±0.05 0.26±0.07 0.22±0.03
Ethanol 1.24 [256] 0.10 [256] 1.21±0.05 0.12±0.02 0.34± 0.02
2-propanol 1.01[257] 0.17[257] 1.04±0.02 0.23±0.02 0.15±0.01
Sucrose 0.52 [258, 259] 0.40 [258, 259] 0.52±0.31 2.4±0.5 0.29±0.02
Glucose 0.67 [260] 0.36 [260] 0.59±0.03 0.8±0.3 0.19±0.02
w = 0-30% (w/w) w = 0-10% (w/w) w = 0-30% (w/w)
T = 298 K T=296 ± 1 K T=296 ± 1 K
drogel, while the concentration at the far end remained zero during each experiment. Dilute
diffusivities (D0) were extracted at early times of the chemical switch at low concentrations,
while the concentration dependence on diffusivity (b) was extracted from the entire time course
of the experiment.
The numerical model, with best fit diffusivity values, shows strong agreement with the
experimentally measured concentration profiles, as seen for ethanol in Fig. 7.4c. This mea-
surement was repeated at least 5 times, on 2 different microchips, for various solutes, and the
best fit values are shown in Table 7.1. The measured values of the dilute diffusivity agree with
previously published literature values for all solutes [255, 256, 257, 258, 259, 260]. Measure-
ments of b agree well with literature values for ethanol and 2-propanol [256, 257]; however,
they are higher than literature values for glucose, glycerol, and sucrose [258, 260, 255, 259]. In
the literature, the diffusion coefficients are measured with very small chemical gradients cen-
tered at different concentrations, while we extract the concentration dependence from a single
steep chemical gradient. We believe the discrepancy for glucose, glycerol, and sucrose is due
to the difference in measurement technique; however, this is still under investigation.
Compared to current diffusivity measurement techniques, our method has many benefits.
Small diffusive length scales enable diffusivities to be measured with less than 5% variability
in minutes. In addition, because concentration profiles are spatially resolved, subtle effects,
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such as diffusivity changes with concentration, can be measured with the technique.
7.4.3 Transport through the PEG-DA hydrogels
Although the FECO fringes are difficult to resolve within the hydrogel, the numerical model
can be extended to include transport through the hydrogels. The effective diffusion coefficient
in the hydrogel was assumed to be proportional to the free solution diffusion coefficient (with
parameter k), independent of concentration:
Dgel(C) = k×Dsol(C). (7.7)
Boundary conditions were measured experimentally and the effective diffusivity in the hy-
drogel was found with least squares regression. The free solution diffusivity was taken from
literature reports (Table 7.1), because concentrations in the gel were much higher than the
concentration range in which free solution diffusivities were determined in this study. The
numerical model shows strong agreement with the experimental data, as shown for ethanol
in Fig. 7.4d. Effective diffusivities within PEG-DA range from 0.15 to 0.35 times the free
solution diffusivity for the solutes tested (Table 7.1).
7.5 Evolution of a chemical gradient in a CDC
Multiple transport processes contribute to the development of concentration fields in CDCs.
The chemical species must diffuse through both the hydrogels and the CDC to fully develop
a steady state concentration profile. Within the gel, the diffusive resistance can vary signifi-
cantly from free solution due to physical effects, such as size exclusion, or chemical effects,
such as partitioning [261]. In addition, the constant diffusion coefficient assumption may fail
when working with concentrated solute mixtures. We now use the technique to measure the
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Figure 7.5: (a) Dimensions of microfluidic chip containing CDC and PEG-DA hydrogels. (b)
Microscopic image of CDC showing spectrometer slit position. (c) Best fit numerical model
using Eqns. 7.5-7.7 (lines) agrees with experimental data (shapes).
generation of a chemical gradient in a CDC directly.
The CDC interferometer consists of three channels, which are connected within a central
region, where the CDC is located (Fig. 7.5a). Photopolymerized hydrogels form the CDC
(Fig. 7.5b) [234]. For all experiments, all three channels were initially filled with a homoge-
nous solute mixture, with a known concentration. After establishing homogenous conditions
throughout the device, flow was stopped to the center CDC channel with external valves. New
solute mixtures were flowed through the exterior channels to generate a chemical gradient
across the CDC. The chemical switches were performed by manually changing external, inlet
tubing.
For the diffusion studies presented here, all three channels were initially filled with an
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average solute mixture, and fluids in the two reservoir channels were replaced with pure water
and a solution with twice the average concentration, respectively. By initially filling the device
with an average solute mixture, the amount of transverse diffusion into the center channel is
significantly reduced. In addition, the length scale required for diffusion is halved, reducing
the time required to reach steady state by 75%.
FECO interferometry was used to track concentration profiles within the CDC and in the
side control channels. The spectrometer slit was positioned perpendicular to the PEG-DA
hydrogels in the center of the CDC (Fig. 7.5b), generating fringe patterns similar to those
shown in Fig. 7.2a. An example experiment displaying the measurement of gradient generation
is shown in Fig. 7.5c. Concentration profiles were not measured within the PEG-DA hydrogels
because FECO fringes are not easily resolved.
The 1D diffusion model (Eqns. 7.5-7.7) and diffusivity measurements (Table ??) were
compared to the measured concentration fields in the CDC. The model accurately predicts the
evolution of the chemical concentration profile, as demonstrated for glycerol in Fig. 7.5c. Ex-
cellent agreement is also observed between the numerical model and experimental data within
the CDC for other glycerol concentrations and for the other solutes tested (ethanol, isopropanol,
glucose, and sucrose). Based on the diffusivity measurements shown in Table ??, many features
of the steady state profile observed in the CDC (Fig. 7.5c) could have been predicted. First, the
concentration drop across the hydrogels is three times greater than the water equivalent due to
the lower diffusivity. In addition, the steady state concentration profile is not completely linear
due to the concentration dependent diffusivity. Notably, the concentration in the center of the
CDC differs slightly from the average concentration of the two side channels.
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7.6 Conclusions on technique utility
We have developed a novel interferometry method to measure concentration fields in situ
in microfluidic devices, without any fluorescent labeling. The technique requires very sim-
ple fabrication steps, and it easy to set up using equipment that is standard in many research
laboratories. The refractometry method has good spatial and temporal resolutions (1 µm and
50 ms, respectively) with a refractive index sensitivity of 10−5 RIU. Here, we have used the
technique to quickly measure binary diffusivities with high precision (less than 5 % error), and
extract both the concentration dependence on diffusivity and effective diffusivity in PEG-DA
hydrogels. The technique was also applied to directly measure the generation of a chemical
gradient in a CDC.
Although the ability to resolve changes in refractive index down to 10−5 RIU is not new, as
other microfluidic interferometry geometries have resolved changes down to 10−7 RIU [247],
the ability to resolve these changes in both space and time makes the technique a useful and
novel tool. We anticipate our technique will prove useful for directly measuring and visualizing
spatio-temporal concentration profiles, opening new possibilities for the direct interrogation of
materials and systems as they equilibrate, react, dissolve, or crystallize.
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The role of adsorption on transport in
PEG-Da hydrogels
Hydrogels are commonly used in drug delivery as particles, drug depots, and tissue scaffolds
due to their unique material properties [262, 263]. The high water content of the gels allow
for molecules to passively diffuse through the gel while the polymer network provides a solid
substrate which can provide structural support. Due to their wide-spread use, there has been
considerable research in engineering new hydrogel systems to precisely control the resulting
gel structure. To fully take advantage of hydrogel utility, there are also significant efforts on
understanding how gel structure and synthesis conditions correlate to functional properties,
such as drug release kinetics and gel elasticity.
A common requirement for hydrogels, regardless of the application, is that material must
transport through the gel. For example, drugs need to be released from hydrogel particles
for therapeutic purposes and nutrients need to be delivered to cells in gel tissue scaffolds.
Furthermore, being able to precisely control and predict these transport processes is critical to
engineering effective hydrogel systems.
Many previous studies have demonstrated that the diffusion of a species can be predicted
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based on the physical properties of the hydrogel, such as polymer molecular weight, cross
linking density, and polymer volume fraction [264, 265]. Based on these models, hydrogels
can be synthesized with different conditions to change the hydrogel structure and resulting
transport properties. However, significantly changing diffusion rates often requires drastic
changes in gel structure which can also influence other critical, material properties in a negative
manner making it challenging to engineer hydrogels with extended release profiles.
On the contrary, diffusion rates can be significantly slower than predicted given the gel
structure, due to interactions between the polymer network and solute. Electrostatic and hy-
drophobic interactions have shown to increase or decrease the partitioning of solutes in hydro-
gels and resulting transport rates [266]. For example, diffusion can be significantly hindered
for proteins [267, 268, 269, 270, 271] and small molecule therapeutics [272, 273, 274, 270,
271, 275, 276] in neutral and ionizable gels . Futhermore, the chemical structure of a gel can
be engineered to interact differently with a solute to control solute partitioning and transport
rates [276].
Polyethylene glycol (PEG) is a commonly used polymer in the field of drug delivery due
to its ability to resist non-specific protein adsorption resulting in PEG’s anti-fouling property
[277]. Surprisingly, the transport of solutes in PEG hydrogels can still be influenced due to
minor PEG-solute interactions [270, 274]. These interactions can lead to unexpected diffusion
rates, impacting the utility of a PEG hydrogel in various drug delivery and/or tissue engineering
applications. Here, we demonstrate experimentally that solute adsorption in PEG-Da hydrogels
significantly impacts solute transport in both transient and steady state conditions. Sodium
dodecyl sulfate (SDS) is used as a model interacting solute because it has shown to interact
significantly with PEG in previous studies [278, 279, 280], while butanol is used as a model
non-interacting solute.
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8.1 Transport in polymeric gels
Various theoretical models have been proposed to describe transport in polymeric gels and
solutions [264, 265]. Diffusion depends greatly on the rigidity and density of the polymer
chains and the ability for solvent to penetrate the polymeric network. In rubbery polymer
systems, the diffusion of species obeys Fickian diffusion. However, in rigid polymer networks,
typically below the glass transition temperature (Tg), diffusion of molecules will also depend
upon the relaxation of the polymer network. The different regimes for diffusion in polymer
networks are often referred to the following based on the relative polymer relaxation time scale
(τrelax) and diffusion time scale (τdi f f ) [265]:
1. Case I: τdi f f >> τrelax, Fickian
2. Case II: τdi f f << τrelax, Non-Fickian
3. Anomalous: τdi f f ∼ τrelax, Non-Fickian
Diffusion of aqueous species in hydrogels is typically Fickian because the gels are already
hydrated with water. Many models have been proposed which accurately predict the diffu-
sion of species based on the physical properties of the gel and diffusant (gel pore size, water
volume fraction, diffusant size, etc.). These models assume that the diffusant only diffuses
in water through the gel pores and that the polymer network retards diffusion through various
physical mechanisms. The physical models typically estimate the diffusivity based on the free
aqueous volume in the gels, increase in hydrodynamic resistance due to the polymer network,
obstruction effects due to the polymer network, or a combination of these effects [264]. The
majority of these models accurately describe transport in gels with large, water volume frac-
tions and with minimal interactions between diffusant and gel. However, in many material
systems, the diffusing species interacts strongly with the gel, significantly impacting transport
processes.
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A simple, theoretical model is used to describe the transport through a polymeric gel with
reversible adsorption. The derivation is similar to the derivation done previously by Liu et al
[276]. The average, local concentration (Ctotal) is assumed to be a summation of the concen-
tration of species in the gel pores (C f ree(1−φ)) and the concentration of species adsorbed on
the polymer backbone (Cadsφ ), where φ is the volume fraction of the polymer in the gel. The
diffusing species is assumed to interact with the polymeric gel with linear adsorption kinet-
ics. The reaction coefficients, kon and ko f f , are effective bulk rate constants for pore surface
adsorption. If the polymer backbone becomes crowded with adsorbing species, a non-linear
adsorption model, such as a Langmuir or Freundlich isotherm, may be required to accurately
model the adsorption. Surface diffusion along the polymer backbone is neglected, which is
valid if the pore diffusive time scale is faster than that of surface diffusion. An effective dif-
fusion coefficient in the gel (Dgel) is used, representing the diffusion coefficient of a species
which does not adsorb onto the gel. There are many theoretical models which can be used to
accurately predict this diffusivity value, typically based on the free volume in the gel or based
on hydrodynamic drag from the polymer strands [264].
Mass balances are shown for the free, adsorbed, and total species (Eqns. 8.1 to 8.3):
∂C f ree
∂ t
= Dgel
∂ 2C f ree
∂x2
− φ
1−φ (konC f ree− ko f fCads) (8.1)
∂Cads
∂ t
= konC f ree− ko f fCads (8.2)
∂Ctotal
∂ t
= (1−φ)Dgel
∂ 2C f ree
∂x2
(8.3)
Eqns. 8.1 and 8.2 can be non-dimensionalized using the diffusive time scale, leading to
Eqns. 8.4 and 8.5, resulting in two dimensionless variables. The equilibrium coefficient (K)
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relates the adsorption rate constant to the desorption rate constant, while the Dahmkohler num-
ber (Da) relates the time scale for diffusion to that of adsorption (Eqn. 8.6). For a species which
significantly adsorbs onto the polymer backbone (K ≥ 1), three general regimes exist for trans-
port in the hydrogel, depending upon the relative time scales for diffusion and adsorption. This
will be discussed in detail in the next section.
∂ ˜C f ree
∂ t˜
=
∂ 2 ˜C f ree
∂ x˜2
−Da φ
1−φ (
˜C f ree− ˜Cads) (8.4)
∂ ˜Cads
∂ t˜
=
Da
K
( ˜C f ree− ˜Cads) (8.5)
K =
kon
ko f f
Da =
L2kon
Dgel
(8.6)
8.2 Experimental and computational methods
Experimental methods
Microfluidic interferometry was used to measure the transport of solutes in PEG-Da hy-
drogels (Fig. 8.1). A Fabry-Perot microfluidic device was fabricated with modification from
a previous study [2]. Glass slides were coated with a semi-reflective coating of Ag/Ti (50/5
nm) with electron-beam deposition, and holes were drilled into the glass slides with a drill. A
microfluidic channel design was cut into photoresist film (KOLON KS-8730, ∼ 30µm thick)
using a laser cutter, and the film was then bonded to one glass slide at 120 oC for 1 min. The
film was sandwiched between another glass slide and baked at 120 oC for 8 min. PDMS inlet
cubes and the top glass slide were treated with UV ozone for at least 5 min., and then the cubes
were bonded to the glass slide in the oven at 120 oC for at least 10 min. After bonding, the
photoresist film was further cured in a UV microwave for 4.5 min.
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PEG-Da hydrogels were synthesized in situ between two channels as previously reported
[234]. Briefly, an aqueous precursor solution containing PEG-Da 400 (33, 40, 50, or 60 vol.
%) and 2-Hydroxy-2-methylpropiophenone (3 vol. %) was flowed into the microfluidic device.
After stopping flow, the precursor was polymerized with an inverted microscope by exposing
a region in the channel to UV light (30 mW, 1 s) through a slit positioned in the shutter (400
or 800 µm wide) with a 4x objective. A representative gel is shown in Fig. 8.1b. After
polymerizing the gel, both channels were flushed with DI water for at least 15 min to remove
the precursor, and the gel was soaked in water for at least 1 d after polymerization to remove
any leftover reactant.
FECO interferferometry was used to measure the refractive index along a line in the mi-
crofluidic device [2]. For each experiment, the device was positioned so the spectrometer slit
was centered on the hydrogel (Fig. 8.1b). FECO fringes were observed both in the aqueous
solution and within the PEG-Da hydrogel (Fig. 8.1c). Fringes were not resolved at the edges
of the hydrogel because of the abrupt change in refractive index; therefore, this region of the
gel was not used in any analysis.
To measure the diffusivity of a solute, the device was initially filled with DI water. The
inlet and outlet of the large channel on the top and the outlet of the thin channel (Fig. 8.1b)
were submerged in a reservoir to ensure no flow in the large channel. The solution in the thin
channel was switched from DI water to solute using a pressure source to provide flow, and
images of the FECO fringes were taken every 1 s. Refractive index profiles (n(x, t)) were then
extracted by tracking the relative shift in the FECO fringes at each position over time using a
MATLAB algorithm described previously [2].
Theory of diffusion measurement
Using the microfluidic device setup described previously, there are two general ways in
which an effective gel diffusivity can be measured. A chemical can be allowed to propagate
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Figure 8.1: (a) Cartoon schematic of Fabry-Perot, microfluidic device (side view) (b) Repre-
sentative image of microfluidic channel with PEG-Da hydrogel polymerized in situ (c) FECO
fringes used to track the diffusion of solute into the PEG hydrogel corresponding to the device
shown in (b)
through a gel, and the transient concentration profiles inside the gel can be fit to a numerical
diffusion model (Fig. 8.2a). The best fit diffusivity, De f f , will be used to describe the transient
diffusivity for a propagating species. On the contrary, a quasi steady state gradient can be es-
tablished across a thin hydrogel slab, and the flux through the gel can be measured to determine
an effective steady state diffusivity, commonly referred to as the permeability (P) (Fig. 8.2b)
[281]. Here, the flux through the membrane is determined by measuring the concentration
profile in the solution at the edge of the hydrogel. The permeability (P) is then calculated by
relating the flux to the concentration drop across the membrane and the membrane thickness.
Depending upon the relative time scale for diffusion and adsorption, the measured transient
diffusivity and permeability (De f f and P) will mean qualitatively different things (Table 8.1).
If diffusion is significantly slower than adsorption (Da >> K), then quasi equilibrium can be
assumed throughout the gel and Eqn. 8.3 simplifies to:
∂Ctotal
∂ t
=
1−φ
1−φ +Kφ Dgel
∂ 2C f ree
∂x2
(8.7)
In this case, the transient diffusion coefficient will be less than the permeability. On the
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Figure 8.2: Differences in diffusion technique.
contrary, if adsorption is slow compared to diffusion (Da << 1), then the species will diffuse
through the gel without adsorbing at short time scales and both the transient and permeability
values will be measured with similar values. If diffusion and adsorption have similar time
scales, the concentration profiles inside the gel will not look strictly diffusive, and a best fit
diffusion value will lie between the two extremes just discussed.
Table 8.1: Measured diffusivity values in hydrogels with adsorption (Assuming K > 1)
Da >> K 1 < Da < K Da << 1
De f f ≈ 1−φ1−φ+Kφ Dgel 1−φ1−φ+Kφ Dgel < De f f < (1−φ)Dgel De f f ≈ (1−φ)Dgel
P = (1−φ)Dgel P = (1−φ)Dgel P = (1−φ)Dgel
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8.3 Transient diffusivity measurements in PEG-Da hydro-
gels
To measure the transient diffusivity, a PEG-Da hydrogel was polymerized as shown in Fig
8.3a. The solution flowing in the left channel was switched from DI water to a solution with
the solute of interest (7 mM SDS, 5 wt. % butanol, or 7 mM DTAB). The refractive index
of the gel was assumed to change linearly with the concentration of diffusing solute, which is
valid for dilute solutes [254]. A 1D numerical diffusion model was then fit to the refractive
index profiles inside the gel after switching solutions, and least squared regression was used to
calculate the best fit diffusivity for each experiment (Fig. 8.3b-c). The outer 10 % of the gel
was not used during the fitting process due to the heterogeneity of the gel on the edges. The
numerical diffusion models fit the refractive index profile qualitatively well for both butanol
and SDS.
PEG-Da hydrogels were then polymerized with different volume fractions of PEG-Da in
the precursor solution (33, 44, 50, and 60 vol %). The final volume fraction of the polymer
in the hydrogel was assumed to be identical to the initial volume fraction of polymer in the
precursor. This approximation should hold becuase the equilbrium water content is similar to
the water content in the precursor solution for hydrogels made with low molecular weight PEG-
Da oligomers (< 600 Da) at these polymer compositions[282]. In addition, no gel swelling was
observed in the microscope after synthesizing the hydrogels; however, it is expected that higher
molecular weight PEG-Da gels would swell and bulge at the sides.
The effective gel diffusivities of SDS and butanol decreases with increasing PEG-Da com-
positions. Based on free volume theory [281], the diffusivity of a solute should scale exponen-
tially with the negative, inverse of the hydration (H) of a polymeric gel. The hydration (H) is
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Figure 8.3: Example refractive index profiles to determine transient diffusivity. (a) Image of
PEG-Da (33 %) hydrogel with spectrometer slit position. (b) Refractive index profile after
switching solution from DI water to 5 wt. % butanol. Experimental data is compared to
1D numerical diffusion model within the hydrogel. (c) Refractive index profile after switch-
ing solution from DI water to 7 mM SDS. Experimental data is compared to 1D numerical
diffusion model within the hydrogel.
defined as the final volume fraction of water in the gel.
De f f α exp(−1/H) where H = 1−φ (8.8)
The effective diffusivities for butanol and SDS in hydrogels made with 33, 40, and 50 vol.
% PEG-Da obey the simple free volume theory (Fig. 8.4). The diffusivity for both butanol and
SDS are higher at 60 vol. % than predicted by the theory. For butanol, the free volume theory
is able to accurately predict the diffusivity of butanol in pure water (H = 1); however, the theory
under predicts the diffusivity of SDS in pure water by 1 order of magnitude. This discrepency
is believed to be due to interactions between the PEG and SDS, which is further measured in
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permeability measurements.
Figure 8.4: Transient diffusivity of butanol and SDS as a function of inverse hydration (1/H)
8.4 Permeability measurements in PEG-Da hydrogels
The quasi steady flux through a PEG-Da membrane was measured to determine hydrogel
permeability (P). To ensure a large flux which can be accurately detected with interferometry
and a short time required to reach quasi steady state, the hydrogels were crosslinked to be half
as thick as the gels used to measure the transient diffusivity (Fig. 8.5a). The concentration drop
across the PEG-Da membrane was measured with the difference in refractive index across the
gel, and the flux through the gel was measured using the slope in refractive index on the side
of the gel with no flow (Fig. 8.5b-c). While the refractive index could be measured in the
hydrogel, a direct correlation between the refractive index and concentration is unknown, mak-
ing it more convenient to measure the flux through the hydrogel membrane with the external
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concentrations in solutions. Summarizing, the permeability was calculated with:
P =
Flux
∆Cgel/∆xgel
=
(∆n∆x )sol
(∆n∆x )ext
Dsol (8.9)
where (∆n∆x )ext is the slope in refractive index drop across the gel and (
∆n
∆x )sol is the slope in
refractive index in solution at the edge of the hydrogel.
Figure 8.5: (a) Microscope image of device used to measure PEG-Da permeability. (b) Rep-
resentative refractive index profiles in device after flowing 5 wt. % butanol (100 s between
each curve). (c) Representative refractive index profiles in device after flowing 7 mM SDS
(200 s between each curve)
The permeability was then calculated by averaging the ratio of refractive index slopes be-
tween 650 to 700 s after switching solutions. A quasi steady state concentration gradient is re-
quired to accurately calculate the permeability using the flux through the hydrogel membrane,
and the effective gel diffusivities suggest this should be achieved within∼ 75 s and∼ 350 s for
butanol and SDS, respectively. Consistent with these time scales, the ratio of refractive index
slope across the hydrogel compared to in solution is approximately constant after flowing bu-
tanol and SDS for 100 s and 400 s, respectively (Fig 8.5b-c). In addition, the refractive index
profile inside of the hydrogels is linear after these time points, further validating the quasi state
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assumption.
Permeability and transient diffusivity values are compared for butanol, SDS, and DTAB
in Table 8.2. While the transient diffusivity and permeability are approximately the same
for butanol, the permeability is approximately 4x and 2x higher than the effective transient
diffusivity for SDS and DTAB, respectively. The large discrepancy between the permeability
and diffusivity for SDS is expected given that SDS interacts strongly with PEG. It is likely that
DTAB also interacts with PEG in a similar manner.
Using the simple adsorption model summarized in Table 8.1, the gel partition coefficient
(Pg,w) and an effective equilibrium constant (K) can be calculated for each species assuming
quasi equilibrium adsorption-desorption in the gel (Da >> K):
Pgw = P/De f f and K = (Pgw +φ −1)/φ (8.10)
Given the differences in permeability and diffusivity for SDS and DTAB, both SDS and
DTAB have relatively high, effective equilibrium constants (K = 10 and K = 3.5, respectively).
On the contrary, the permeability and diffusivity measurements seem to indicate that butanol
does not interact as strongly with the PEG-Da gels (K = 0.83).
Table 8.2: Measured diffusivity values in PEG-Da hydrogels (φ = 0.33)
Diffusivity values (µm2/s) Extracted values
Species Solution
(Dsolution)
Transient
(De f f )
Permeability
(P)
Equilibrium
constant (K)
Partition
coeff (Pg,w)
Butanol 780 293±47 277±39 0.83 0.95
SDS 980 61±11 250±61 10.4 4.09
DTAB 880 137 250±29 3.5 1.8
Permeabilities were measured for SDS and butanol at different PEG-Da volume fractions,
and compared to the transient diffusivity values measured previously (Fig. 8.6). At each gel
composition, the permeability is 3.5 to 5 times faster than the transient diffusivity for SDS. The
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estimated effective equilibrium constants are 10.4, 8.0, 9.2, and 6.4 for the 33, 40, 50, and 60
vol. % gels, respectively. On the contrary, the transient diffusivity is approximately the same
as the permeability for butanol within all of the hydrogels.
Figure 8.6: Transient diffusivity and permeability values for (a) 5 wt. % butanol and (b) 7
mM SDS in PEG-Da gels as a function of PEG-Da volume fractions. Data represents mean
±95% confidence intervals.
To further validate that SDS partitions into PEG-Da hydrogels, macroscopic PEG-Da gels
(φ = 0.33) were synthesized in a UV microwave using a PDMS template to control the size of
the disks. The PEG-Da disks were soaked in 3.5 and 7 mM SDS solutions for 2 days. After
soaking, the concentration of SDS in the solution outside of the gels was measured using a
spectrophotometric technique described previously [283]. By performing a mass balance, the
partition coefficient of SDS in the hydrogel could be calculated. Relatively consistent with the
transport studies, the partition coefficients (Pgw) for 3.5 and 7 mM SDS were determined to be
3.1±0.5 and 3.2±0.2, respectively.
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8.5 Loading and unloading PEG-Da posts
To this point, quasi-equilibrium has been assumed in the hydrogels for butanol, SDS, and
DTAB to estimate an effective, gel equilibrium constant. The refractive index profiles fit
the diffusion equation well when extracting transient diffusivities, giving evidence that quasi-
equilibrium is a valid assumption. The quasi-equilbrium assumption can be further validated
by looking at the loading and unloading of solute from a hydrogel post. This experiment is
done under flow, to ensure minimal external mass transport resistance.
For solutes which partition heavily into the hydrogel (K >> 1), the time required to fill a
hydrogel post with solute can be significantly less than the time required to unload the same
hydrogel post, if equilibrium is never established. If the adsorption time scale is significantly
slower than that of diffusion (Da << K), it can take a factor of K longer to unload a hydrogel
post which was loaded with solute but not in equilibrium with the external solution.
For demonstration, PEG-Da hydrogel posts (φ = 0.33) were loaded with solute by flowing
solutions with SDS (7 mM) and butanol (5 wt. %) past the post for 700 s (Fig. 8.7a). After
flowing the solutions, water was flowed past the posts to unload the posts. For both butanol and
SDS, the time required to load and unload the hydrogel posts is approximately the same (Fig.
8.7b-c), giving further evidence that the gels were at equilibrium with their external solutions.
8.6 Discussion on transport in PEG-Da hydrogels
Understanding solute transport in hydrogels is critical for designing effective gels for var-
ious applications. Many theoretical models can accurately describe transport in gels based on
the physical structure of the gel and diffusant; however, the majority of these models fail to
accurately predict transport in gels with significant solute-gel interactions. Furthermore, while
simple physical models can be used to understand how these interactions impact transport
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Figure 8.7: (a) Microscope image of device used to load up cylindrical PEG-Da post. (b)
Experimental refractive index profile of 7 mM SDS loading (left) and unloading (right) a
PEG hydrogel post (175 s in between each profile). (c) Experimental refractive index profile
of 5 wt. % butanol loading (left) and unloading (right) a PEG hydrogel post (30 s in between
each profile).
properties, few experimental techniques exist to measure these properties directly. For exam-
ple, current experimental techniques rely on measuring the transport of fluorescent solutes,
with techniques such as fluorescence recovery after photobleaching (FRAP) or fluorescence
correlation spectroscopy (FCS), or by measuring self diffusivity values with NMR techniques.
In addition, many studies have extracted effective gel diffusivity and permeability values by
measuring the external concentration of solute in reservoirs which are exposed to hydrogels,
but these techniques are time consuming and do not directly track solute transport in the gels.
Here, a microfluidic, interferometric technique was used to directly measure non-fluorescent
solute transport in hydrogels. The technique is capable of measuring effective gel diffusivity,
gel permeability, and gel loading/unloading time scales simply by changing the geometry of
the hydrogel in the microfluidic channel. A simple adsorption-diffusion model predicts how
solute-gel interactions impact these transport properties. Specifically, the relative rate of diffu-
sion to adsorption/desorption determines the impact of these interactions on solute transport.
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Due to their wide-spread use, PEG hydrogels are used as a model system to demonstrate the
impact of gel-solute interactions on transport.
PEG hydrogels are commonly used in the field of drug delivery due to their ability to re-
sist protein adsorption, and they are generally believed to be relatively inert to solutes. By
measuring the transient and steady state transport of solute in PEG hydrogels, we demonstrate
that certain solutes do interact with PEG and, as a result, transport is significantly impacted.
The effective diffusivity of butanol in PEG-Da hydrogels obeyed simple free volume theory,
consistent with previous reports for NaCl in PEG-Da gels[282]. On the contrary, SDS diffusiv-
ity values in PEG-Da gels were an order of magnitude lower than expected given free volume
theory.
There is a large difference between the permeability and diffusivity for SDS and DTAB;
however, the values are approximately the same for butanol. The large difference in the per-
meability and transient diffusivity measurements for SDS and DTAB, suggest that surfactant
interactions with PEG are responsible for the slow diffusion rate. Gel equilbrium constants
(and partition coefficients) are estimated based on the permeability and transient diffusivity
measurements. Both SDS and DTAB interact strongly with the PEG gel (K = 10 and 3.5, re-
spectively), while butanol did not interact strongly (K = 0.85). The partitioning of SDS into the
hydrogels was verified by also measuring the external concentration of SDS solutions which
were soaked in macroscopic PEG-Da gels.
Previous diffusion measurements in charged HEMA/MAA hydrogels, show that drug trans-
port is significantly impacted by specific drug-gel interactions [276]. Here, we show that a
similar phenomena occurs in neutral PEG-Da hydrogels with the surfactants SDS and DTAB.
While the transport of these surfactants in PEG gels are likely not of interest for the majority of
PEG gel applications, specific interaction between PEG-solute interactions are going to present
in other physical systems impacting transport.
The large difference in permeability and transient diffusivity for solutes which interact
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strongly with gels, significantly impacts the performance of a gel. For example, the time re-
quired for a nutrient to reach a cell encapsulated in a hydrogel can take a factor of Kφ longer
than expected without any solute-gel interactions; however once the nutrient reaches the cell,
the flux of the nutrient to the cell will remain constant regardless of the gel-solute interactions.
Furthermore, as a delivery vehicle, both the quantity of drug loading and time scale for re-
lease are impacted by solute-gel interactions. Favorable gel-solute interactions can increase
drug loading and release time scale by a factor of Kφ . In the specific case where diffusion is
much faster than adsorption/desorption (Da << 1) for strongly associating solutes, it can take
a factor of K longer to release drug loaded hydrogel particles than it does to load the particles,
impacting particle design.
Overall, hydrogels are a useful tool in drug delivery and in other material systems due to
their ability to allow for fast solute transport. Solute-specific interactions with gels impact
transport rates, and, therefore, hydrogel function as demonstrated with PEG gels here. It is
critical that the effect of gel-solute interactions are measured experimentally and accurately
accounted for in physical models to ensure gels are engineered to function properly in a given
application.
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Conclusions and future directions
Advancements in drug delivery have the potential to significantly improve the treatment of
many diseases; however, designing an effective delivery system requires overcoming many
biologic, material, and engineering challenges which has resulted in few approved clinical
products. For the field to continue to progress, a focus needs to be placed on developing
clinically feasible delivery platforms. Furthermore, more fundamental studies need to address
how to optimize the physio-chemical properties of these delivery vehicles to most effectively
release their drug payloads and interact with their intended biological systems.
This thesis has focused primarily on developing delivery systems for the treatment of breast
cancer. Specifically, clinically relevant delivery vehicles were designed to carry synergistic
combinations of FDA approved chemotherapeutic agents. Release kinetics of drugs were op-
timized to increase the efficiency of delivery vehicles by improving drug-drug interactions.
In addition, a new microfluidic tool was developed to study drug release in hydrogel-based
delivery systems, for future delivery vehicle development.
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9.1 Identification of synergistic drug pairs with in vitro as-
says
Using a combination of therapeutics is commonly employed in the clinic for various dis-
eases based on the methodology that targeting multiple pathways can more efficiently target
the disease state. In oncology, doctors are constantly trying new chemotherapeutic combina-
tions to treat late stage cancers which are unresponsive to standard treatment regimes. Because
mono-chemotherapy is limited by toxicity at higher doses, combination chemotherapy is only
an effective treatment option if a lower combination drug dose can be administered to achieve
a greater reduction in tumor burden. The identification of synergistic drug pairs with non-
overlapping mechanisms of toxicity can help solve this problem.
Many in vitro studies have shown that drug synergy is extremely sensitive to specific pa-
rameters, such as drug dose and drug ratio; however, an often overlooked parameter impacting
drug synergy is the schedule in which the cells are exposed to the drugs. In my disserta-
tion, I have shown that synergy between many of the commonly used chemotherapeutic agents
is significantly impacted by drug scheduling on various breast cancer cell lines. Using the
Chou-Talalay synergy method, I have identified synergistic drug schedules for different breast
cancer cell lines. I have studied in detail synergy between GEM and DOX on triple negative
breast cancer cells (MDA-MB-231) and between LAP and PTX on HER2+ breast cancer cells
(BT-474). For both drug pairs, I have shown that bolus scheduling of the drugs impacts how
effective the pair is at inhibiting tumor growth in vitro.
Using the Chou-Talalay method, giving GEM prior to DOX was found to be more effective
than other administration schedules in vitro. Furthermore, the cells were found to undergo
significantly more apoptosis when exposed to these drugs in the optimal sequence. The cell
cycle distribution of the cells gave insight into why the cells seemed to be more prone to DOX-
induced toxicity after exposure to GEM. From the in vitro studies alone, it was clear that drug
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schedule significantly impacts how effective the GEM/DOX combination is at inhibiting tumor
growth.
The combination of GEM and DOX was also effective at inhibiting tumor growth in vivo;
however, surprisingly, the administration sequence of the drugs did not play a significant role
in efficacy. While the discrepancy between the impact of administration schedule on in vitro
and in vivo tumor reduction requires further evaluation, there are multiple observations that
may explain these discrepancies. First, cells are known to behave differently in vitro compared
to an in vivo environment. For example, while GEM had a significantly higher IC50 than DOX
in vitro, GEM was more effective at inhibiting tumor growth in vivo. In addition, due to fast
clearance of small molecules, the cells in vivo are exposed to different concentrations of drug
which may not produce the same synergistic effects. For example, GEM has an extremely
short half life in mouse plasma due to rapid deamination, resulting in lower cumulative drug
exposure than tested in in vitro studies.
In spite of the discrepancy in schedule dependency of GEM and DOX between in vitro and
in vivo assays, the drug pair was much more effective than the single drugs in vivo. Further-
more, the drug pair was effective at inhibiting tumor growth at low drug doses, which did not
cause any observable signs of toxicity. The in vitro identification of synergy between GEM
and DOX led to a drug pair which performed favorably in vivo; however, it is clear that the
optimization done in vitro did not translate to in vivo.
Moving forward, it is believed that identification of drug synergy is a critical tool in picking
effective drug combinations. It is also evident that the sequence in which cancer cells are ex-
posed to chemotherapeutic agents in vitro significantly impacts how effective the drugs are at
inhibiting cell growth. However, more sophisticated in vitro models are required to accurately
predict in vivo activity. For example, spheroid cultures which more accurately represent the
tumor microenvironment and realistic drug exposure profiles will assist in creating more pre-
dictive in vitro models. Furthermore, synergy needs to be evaluated on patient derived tumor
130
Conclusions and future directions Chapter 9
cells, due to the large degree of heterogeneity from patient to patient. Synergy should also
not be viewed as static and be reevaluated throughout the course of treatment, due to the rapid
development of drug resistance.
Unfortunately, many drug pairs which were identified as synergistic in vitro still fail to re-
sult in any improvement in clinical efficacy. Because drug pairs are often administered based on
optimized mono-chemotherapy dosing regimes, it is not surprising that it is difficult to translate
synergistic drug pairs from the bench top to the patient. Adjusting chemotherapeutic dosing
schedules and ranges based on drug-drug interactions should improve combination chemother-
apy in many cases. Furthermore, the development of new delivery vehicles carrying precise
combinations of therapeutic agents, should improve the ability to translate drug pairs from the
lab to the clinic.
9.2 Design of synergistic delivery vehicles
The development of drug delivery systems carrying multiple chemotherapeutics has grown
significantly in the past decade, in hopes of combining the potential therapeutic benefits of
combination chemotherapy and nanoparticulate delivery systems. It is a synthetic and engi-
neering challenge to synthesize a delivery vehicle capable of carrying multiple drugs due to
the large differences in physiochemical properties of various drugs. Furthermore, there are
many design parameters which impact therapeutic efficacy, including delivery vehicle physical
properties, drug ratio, and drug release rates. While many studies have shown the ability to in-
corporate multiple drugs into a single delivery vehicle, few have studied how design parameters
impact the efficacy of the vehicle and drug-drug interactions.
Combining multiple chemotherapy drugs into a single delivery vehicle is only advanta-
geous, if the drugs work favorably together. As just discussed, administration schedule sig-
nificantly impacts the synergy between the two drugs. In my dissertation, I have engineered
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delivery vehicles which can be optimized by changing the release rate of drugs from the de-
livery vehicle. Drug pairs, which demonstrate a strong dependence between synergy and drug
schedule, were loaded into polymer drug conjugates and bi-phasic nanoparticles. The syn-
thetic techniques of the delivery vehicles allows for the relative release rate of each vehicle to
be changed without significantly changing the delivery system.
HA based conjugates were synthesized with DOX and GEM. Based on which chemical
linker the drugs were conjugated to HA with, the relative release kinetics could be changed
without changing the physical structure of the vehicle. HA conjugates which released GEM
faster than DOX were synergistic at inhibiting cancer cell growth in vitro, as predicted with free
drug scheduling studies. Furthermore, the dual drug HA conjugates were much more effective
at inhibiting tumor growth in vivo than the single drug conjugates.
Similarly, bi-phasic nanoparticles, consisting of PLGA and acDEX, were synthesized with
EHD co-jetting and loaded with LAP and PTX. The compartments degrade and release their
therapeutic payloads at different rates, depending on the composition of the polymer, and LAP
and PTX could be loaded into different compartments simply by changing the jetting condi-
tions. The toxicity of the bi-phasic particles on cancer cells in vitro was highly dependent upon
which compartment the drugs were loaded into the particles, demonstrating the importance of
drug release kinetics.
While both delivery platforms were optimized to deliver a defined drug pair to treat a spe-
cific breast cancer cell line, the same platforms can be applied to treat additional cancers with
other synergistic drug pairs. The ability to maintain the physical structure of the vehicle, while
manipulating which drugs are incorporated, the ratio in which these drugs are combined, and
the relative drug release kinetics, provide a framework to optimize drug interactions for any
given disease. Furthermore, these studies motivate the future development of delivery systems
capable of controlling the temporal release of multiple therapeutics with higher precision. Both
passive and externally stimulated release mechanisms are anticipated to play a role in future
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development.
It is evident that nanomedicine will play a critical role in the future of combination chemother-
apy; however, the future success is highly dependent upon the collaboration of material scien-
tists, chemists, biologists, and clinicians. Future research needs to focus both on gaining a
better fundamental understanding how these complicated material systems interact with bio-
logical systems and how to develop clinically feasible delivery platforms. Both gaining a better
understanding of how the material properties of the carrier impact vehicle internalization and
biodistribution in vivo and how drug incorporation impacts the efficacy of the vehicle are neces-
sary to develop effective vehicles. Furthermore, developing simple delivery systems, utilizing
materials which are already approved for clinical use and scalable synthetic techniques, will
help streamline the process of future clinical translation.
9.3 Clinical translation of hyaluronic acid drug conjugates
Given the high failure rate of single drug loaded vehicles in the clinic, it is not surprising
that few dual loaded drug nanomedicines have been evaluated in clinical trials. However, the
recent success of the dual drug loaded liposome Vyxeos in treating acute myeloid leukemia
(AML) in phase III clinical trials, provides evidence that multi-drug incorporation has the po-
tential to transform future therapies. Unfortunately, incorporating multiple drugs into a single
delivery vehicle is challenging and results in complicated synthetic routes, making it difficult
to overcome the stringent regulatory approval process required for such multi-functional and
multi-drug incorporated systems. In spite of these challenges, it is believed that the HA-DOX-
GEM conjugates developed in this dissertation warrant further investigation as a potential clin-
ical product due to the simple synthetic steps, effectiveness in an aggressive pre-clinical cancer
model, and the potential to treat other cancers.
The synthesis of HA based drug conjugates require basic chemical steps which can easily
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be scaled up by pharmaceutical companies. Compared to liposomes and polymeric nanopar-
ticles, polymer drug conjugates require more traditional synthetic steps. In addition, after the
final vehicle is synthesized, the polymer drug conjugates can be stored as a lyophilized powder,
increasing the shelf life compared to liposomes which must remain hydrated. However, prior
to translation, more research is required to gain better control of the final physical structure of
the vehicle. For example, while conjugation of GEM to HA does not seem to have any impact
on vehicle structure, conjugation of hydrophobic drugs, such as DOX, can lead to both vehicle
self assembly and aggregation, which needs to be better understood and controlled for future
translation.
Regardless of the ability to synthesize a reproducible product, clinical activity ultimately
determines the success of a given therapeutic. HA based drug conjugates have previously
shown efficacy in preclinical models, and, here, we show that HA-DOX-GEM is effective at
treating an aggressive, orthotopic, 4T1 tumor model. Due to synergy between DOX and GEM,
low drug doses can be administered leading to tumor growth inhibition with no observable signs
of toxicity. Interestingly, HA-DOX-GEM is able to treat the cancer systemically both though
intravenous and subcutaneous drug administration. Current research is underway to understand
the distribution of drug and HA carrier through each administration route. Contrary to HPMA-
based drug conjugates, HA drug conjugates can be degraded in various tissues throughout the
body due to the high abundance of hyaluronidases, allowing for the exploration of different
drug administration routes. Future research will need to identify the most optimal way to
deliver HA-conjugates based on target disease pathology in more sophisticated in vivo cancer
models.
HA-based drug conjugates are a broad delivery platform that has the potential to treat can-
cers with very different pathologies. The overexpression of CD-44, the receptor for HA, in
many cancers, warrants the exploration of HA as a drug carrier in different cancers. Further-
more, because HA can be administered through various parenteral administration routes, it can
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be used to treat cancers locally and metastastes that have spread throughout the body. The
future application of HA-based drug conjugates requires collaboration with oncologists, which
can help identity the best application for the technology.
9.4 Development of tools to measure release kinetics
In addition to developing more effective dual-drug loaded systems for treating advanced
cancers, this thesis has developed a broad experimental technique capable of studying how
delivery vehicle release therapeutic payloads. By understanding the mechanisms in which
drugs are released from polymeric systems, drug release rates can be optimized in any given
material system. As discussed in Chapters 5 and 6, drug release kinetics can significantly
impact the therapeutic activity of a drug delivery system. Therefore, to engineer therapeutically
effective delivery vehicles, drug release mechanisms need to be well characterized.
Many simple, physical models can accurately describe the passive release of therapeutics
from polymeric systems. These models rely on predicting polymer degradation rates, drug
linker hydrolysis rates, drug transport rates in polymeric systems, or a combination of these
mechanisms. However, due to specific polymer-drug interactions, drug release cannot be pre-
dicted accurately a priori in many polymer systems and must be measured experimentally.
Typically, drug release is measured macroscopically with dialysis experiments. While these
experiments often give an accurate measurement of the time scale for drug release, they fail to
measure drug release rates with high temporal resolution, making it difficult to understand the
physical mechanisms responsible for drug release rates.
Here, I have developed and characterized a microfluidic technique capable of measuring
solute concentration fields with high temporal and spatial resolution. The technique mea-
sures solution refractive index, and is therefore not limited to measuring fluorescent or UV-
active species, making it broadly applicable to almost all drugs. The utility of the technique
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was demonstrated by the ability to detect subtle changes in solute diffusivity with concentra-
tion, which required accurately measuring solute concentration in a channel with high spatio-
temporal resolution. While this experiment did not measure drug release from a polymeric car-
rier, manipulation of microfludic channel geometry can allow for experiments to be designed
to study drug release or polymer degradation rates.
The technique was then used to study the transport of solute in PEG hydrogels, which are
are commonly used in drug delivery as drug carriers, cell scaffolds, and drug depots. Inter-
estingly, the diffusion of a few ionic surfactants in PEG gels is slower than predicted with
traditional gel transport models. By measuring solute transport rate in and out of the gels, gel-
solute interactions are hypothesized to be responsible for differences in transport rates. These
specific interactions significantly impact the time scale for drug release and drug loading ca-
pacity, which both were effectively measured using the new, microfluidic technique.
While the exact physical system studied here is not applicable to most drug delivery ap-
plications, drug-polymer interactions will be present in many drug delivery systems. These
interactions will significantly impact drug release rates and resulting therapeutic activity, and,
thus, need to be well characterized for the successful engineering of polymeric carriers. The
ability to measure transport and drug release rates with high temporal resolution was demon-
strated here, and it enabled a better fundamental understanding of the mechanisms responsible
for solute release.
The future success of drug delivery is not only dependent up on the development of novel
delivery systems, but also gaining a more fundamental understanding how current delivery
systems interact with their biological targets and therapeutics. Currently, there are few ex-
perimental techniques capable of probing how drugs interact with and release from polymeric
systems. The development of more novel, experimental techniques, capable of measuring drug
release with high temporal resolution, will allow for delivery systems to be engineered to be
more effective. These techniques will lead to both new delivery systems and to new theoretical
136
models capable of accurately predicting drug release in specific systems.
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